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 Summary 
 
The extraordinary evolutionary adaptation of viruses to different hosts and environments, 
though often hostile, makes them valuable tools for gene therapy. Gene therapy seeks to cure 
a disease by “correcting” the underlying cause of the illness, defective or mutated genes, 
through transfer of functional or curative gene constructs into affected cells or tissues.  
Duchenne muscular dystrophy (DMD) is the most common X-linked lethal disorder, 
occurring in approximately 1 in 3500 male births. Affected children are generally confined to 
a wheelchair by their early teens due to limb muscle weakness, and death eventually occurs 
during the third decade of life as a result of either respiratory or cardiac muscle failure. 
Deficiency of the 427kDa protein dystrophin is the causative molecular event leading to 
DMD. Due to the large size of dystrophin cDNA (14kb), the choice of suitable vectors for 
gene therapy is currently limited to non-viral DNA and adenovirus vectors. However, 
adenovirus-mediated gene transfer into skeletal muscle is hampered by low efficiency. The 
inefficient transduction of adult skeletal muscle by adenovirus may be linked to the lack of 
primary (coxsackie-adenovirus receptor CAR) and secondary (αv integrins) virus attachment 
receptors. Therefore, the molecular events involved in attachment and internalization of 
adenovirus were evaluated on the level of primary human muscle cells. Adenovirus 
attachment to primary human muscle cells involved initial binding of two receptors: CAR and 
heparansulfate proteoglycans. In agreement with the proposed two-step model for adenovirus 
infection, internalization of adenovirus was dependent on interaction with αvβ3 integrin. It 
was shown previously that CAR expression on skeletal muscle decreases with age. Therefore, 
we aimed to modify adenoviral vectors by redirecting them to abundant muscle-specific 
receptors. The goal was to simultaneously increase the transduction specificity and efficiency 
for skeletal muscle by means of retargeting adenovirus vectors. Finding the appropriate 
muscle-cell specific receptors necessitated the development of a targeting platform. Since 
molecular and structural data were available for Ad5 virus-receptor interaction, and insertion 
of small targeting ligands into the HI loop of adenovirus knob protein had already been 
demonstrated, the HI loop was chosen as the site for insertion of a 33-amino-acid long 
antibody-binding domain derived from staphylococcus protein A. Functional insertion of this 
domain allowed us to screen potential receptors by simply interchanging the retargeting 
monoclonal antibody before Ad-mediated transduction. Indeed, we were able to show that the 
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HI loop was flexible enough to accommodate larger targeting ligands and, moreover, that the 
33-amino-acid long Fc-binding domain retained full functionality within the context of the HI 
loop and bound antibodies with high affinity. Screening with antibody-retargeted vectors led 
to the identification of two muscle-specific candidate target receptors: neuronal cell adhesion 
molecule (NCAM) and α7β1 integrin. Retargeting of adenovirus to these receptors enhanced 
transduction of myoblasts and myotubes in a specific way. Binding of antibody-retargeted 
adenoviruses to muscle cells was independent of binding to CAR, the natural cellular receptor 
of Ad5. Further experiments are underway to test this new strategy in vivo. In the second part 
of this work, the effectiveness of a different adenovirus serotype vector, based on Ad19a, for 
efficient transduction of muscle cells was explored. To date, 51 human serotypes with distinct 
tropisms have been described. Most adenovirus vectors used for gene therapy are based on 
serotypes 2 and 5 (Ad2; Ad5). The ability of the EGFP-expressing Ad19a-based vector 
(Ad19aEGFP) to transduce primary cells, including differentiated human myotubes that are 
otherwise difficult to transduce with Ad5, was explored. Transduction of a panel of myoblasts 
originating from different species revealed a human-cell-specific infection profile for the 
Ad19a-based vector. Unlike Ad5EGFP, attachment of Ad19aEGFP to human myoblasts was 
mainly dependent on α(2-3)-linked sialic-acid-containing receptors. Transgene expression 
after Ad19aEGFP-mediated gene transfer was increased 10-fold in smooth muscle cells, up to 
78-fold in human myoblasts, and 19-fold in human myotubes as compared to Ad5. 
Determination of viral particle numbers by means of real-time PCR in transduced myoblasts 
of different species revealed two putative transductional barriers for Ad5EGFP and 
Ad19aEGFP vectors. A post-internalization block in pig and ape myoblasts was observed for 
Ad19aEGFP, where high numbers of intracellular particles accumulated without expressing 
EGFP. Second, an early block probably occurred at the level of virus attachment and 
internalization in primary mouse and rat L6 myoblasts, where low numbers of intracellular 
Ad5EGFP and Ad19aEGFP particles could be detected. Moreover, Ad19aEGFP transduced 
monocyte-derived dendritic cells significantly better than Ad5. In summary, this work 
demonstrates that the HI-loop of Ad5 can be used for the insertion of large functional ligands 
like the antibody-binding domain Z33. Moreover, the developed antibody-based retargeting 
strategy for Ad5 proved useful for screening and identification of alternative attachment 
receptors on primary human muscle cells, and may therefore be extended to other cell lines 
and target tissues. Retargeting of Z33-modified adenovirus vector (AdFZ33βGal) to NCAM 
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and α7 integrin increased the transduction efficiency of differentiated human muscle cells 
(myotubes) by 67- and 77-fold, respectively. Since myotubes are a good in vitro model for 
adenovirus transduction of skeletal muscle, the ability of NCAM and α7-integrin-retargeted 
adenovirus to transduce skeletal muscle in vivo shall be explored in the future. Attempts to 
transfer the enhanced muscle-cell-transduction capability of Ad19a to Ad5 are the subject of 
ongoing research. The Ad19a fiber protein shall be transferred to Ad5 and a chimeric virus 
generated. Despite recent advances in the field of gene therapy and vector development major 
hurdles still have to be overcome until gene therapy will be a safe clinical option to treat 
hereditary diseases. The development of safe adenovirus vectors for gene therapy, which do 
not integrate into the host genome, is essential if large cDNAs like dystrophin have to be 
transferred. Retargeting of adenovirus vectors to muscle-specific receptors, as demonstrated in 
this work, led to transduction of muscle cells in a specific way while using less vector 
particles, and may contribute to an improvement in safety and efficacy of adenovirus vectors 
in muscle-directed gene therapy applications. 
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Introduction 
 
From basic interaction of adenovirus with the cell surface to gene therapy of muscular 
dystrophies 
 
1.1 Molecular events involved in cell binding and entry of adenovirus serotype 5 
The infectious pathway of adenovirus serotype 5 involves attachment to the cell membrane, 
very efficient virus uptake upon receptor-mediated endocytosis, directed intracellular 
transport, and nuclear uptake of adenovirus DNA. During this process adenovirus particles are 
dismantled stepwise and the infectious DNA is liberated from the protecting capsid (Fig.1). 
The molecules involved in each distinct step are discussed below. 
 
Fig.1 Infectious pathway of subgroup C adenoviruses. Subgroup C adenoviruses bind to the cellular receptor 
CAR and to alternative attachment receptors like heparansulfate-containing proteoglycans (HSPGs) (I). Uptake 
of viral particles occurs through receptor-mediated endocytosis upon interaction of the adenovirus penton base 
protein with cellular αv integrins (I+II). Signaling through β3 integrins results in PI3K kinase activation, which 
in turn induces dynamin-dependent endocytosis in clathrin-coated vesicles and leads to activation of small Rho 
GTPases Rac1 and Cdc42. Loss of fiber proteins and partial uncoating of adenovirus particles occurs in early 
endosomes. Acid-dependent virus escape from early endosomes (III) is followed by dynein-dependent transport 
on microtubles towards the center of the cell (IV). Complete disassembly of viral particles and nuclear import of 
viral DNA occurs at the nuclear pore complex (NPC) where adenovirus hexon protein directly interacts with 
nuclear pore complex filament protein Nup214/CAN. At the NPC, hexon associates with histone H1, which in 
turn is recognized by importin β and mediates the translocation of hexon-histone H1complexes across the NPC 
(V).  
 
1.1.1 Primary receptors involved in adenovirus binding 
To date 51 human serotypes have been identified and classified into 6 subgroups (A to F)1. 
Subgroup B adenoviruses use CD46 as a cellular attachment receptor2,3,4, whereas sialic acid 
is likely to function as a cellular receptor for subgroup D adenoviruses causing epidermal 
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conjunctivitis5,6. Subgroup C adenoviruses use separate receptors for attachment and entry. 
While the attachment of the virus to the cell is mediated by high-affinity binding to a 46 kDa 
receptor, termed coxsackie-adenovirus receptor (CAR)7,8, internalization of the virus occurs 
through endocytosis upon interaction of the penton-base protein with αv integrins9,10. CAR 
functions as an attachment receptor for type B coxsackieviruses, as well as for many human 
adenovirus serotypes from subgroups A, C, D, E, and F, and also for adenoviruses from 
different species11,12,13.  
CAR is a member of the immunoglobulin receptor superfamily, forms homodimers between 
molecules, and is a functional part of the tight junction where it mediates cell-cell contacts 
14,15,16. Due to the presence of a basolateral targeting signal in the cytoplasmic domain of 
CAR, exclusive basolateral localization of CAR in polarized epithelial cells has been 
observed17. In well-differentiated epithelial airway cells CAR was found below the tight 
junctions as part of the adherens junction where it colocalizes with β-catenin18. 
Adenovirus fiber knob binds with high affinity to a region overlapping the CAR:CAR binding 
interface and competes for CAR-binding on the cell surface14,19,20. CAR is sequestered in tight 
junctions and along the basolateral membrane. How Ad5 infects the polarized respiratory 
epithelium is still a matter of debate. It is unlikely that incoming Ad bind CAR in tight and 
adherens junctions. Infection may start in regions with localized CAR expression on the apical 
surface, as observed in lesions of the epithelium, or might involve other receptors. Instead of 
serving as an adenovirus attachment receptor, binding to CAR may also facilitate the 
adenovirus’ escape and virus spread from the airway epithelium. It has been proposed that the 
excess fiber protein produced during viral propagation in addition to the large amount of 
defective adenoviral particles, which outnumber the functional infectious particles, may 
together lead to the sequential disruption of cell adherens and tight junctions, enabling 
adenovirus escape to the apical surface18,21.  
Various adenovirus serotypes bind to CAR, although the in vivo tropism varies considerably22. 
For instance, Ad40 and Ad41 from subgroup F readily infect cells of the gastrointestinal tract 
and are associated with gastroenteritis. Serotypes Ad8, Ad19a, and Ad37 (subgroup D) are 
associated with epidemic keratoconjunctivitis, and Ad4 (subgroup E) is associated with 
pneumonia22. Since CAR forms homodimeric complexes between neighboring cells, it may 
not be accessible to adenovirus in most tissues. It is therefore not surprising that a number of 
alternative attachment receptors have been described recently for adenovirus serotype 5, 
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involving heparansulfate proteoglycans  (HSPGs)23,24, MHC class I α2 domain25, and α3β126. 
Some adenoviruses (e.g., Ad9) use the penton base protein instead of the fiber protein for 
attachment27. The penton base protein from Ad5 might also be involved in direct binding to 
the cell surface, as demonstrated by binding of Ad5 penton base protein to integrin αMβ228.   
 
1.1.2 Adenovirus internalization and clathrin-mediated endocytosis 
Efficient internalization of adenovirus particles requires a second interaction with 
internalization-promoting receptors. The Ad5 penton base binds to integrins αvβ3 and αvβ5 
through its RGD motif and mediates internalization of Ad5 through receptor-mediated 
endocytosis in clathrin-coated pits9,29. Binding of penton base protein to vitronectin-binding 
integrins αvβ3 and αvβ5 induces discrete conformational changes that lead to receptor 
activation and induce signaling events that mediate clathrin-coated pit endocytosis and 
enhance macropinocytosis30,31. Low expression of adenovirus receptor CAR and αv integrins 
in peripheral blood mononuclear cells (PBMCs) correlates with low transduction efficiency of 
these cells. Relevance of αv integrins for efficient transduction by subgroup C adenoviruses 
was demonstrated upon upregulation of αv integrins by specific growth factors (macrophage 
colony-stimulating factor or granulocyte-macrophage colony-stimulating factor), which 
increased Ad5-mediated gene delivery to PBMCs32. Primary attachment of Ad5 to PBMCs is 
thought to occur via binding to αmβ2 integrin but still requires binding to integrins αvβ3 and 
αvβ5 for internalization28. 
Clathrin-mediated endocytosis involves initial recruitment of the heteroterameric clathrin 
adaptor complex AP2 or neuronal accessory clathrin adaptor protein AP180 to the plasma 
membrane followed by binding of clathrin to the adaptor and assembly of the coat30,33. 
Vesicle constriction and fission requires the GTPase dynamin, which self-assembles at the 
collar of invaginated coated pits to forms a ring-like structure34.  
Many components involved in clathrin coated vesicle formation interact specifically with 
PtdIns(4,5)P2, which seems to be critically important in the recruitment of AP-2/clathrin coats 
to membranes35,36. The importance of PtdIns(4,5)P2 for vesicle integrity was demonstrated by 
the involvement of synaptojanin-1, a phosphatidylinositol-5 phosphatase, in the regulation of 
clathrin-coated vesicle uncoating36. 
The interaction of Ad5 penton base with av integrins mediates activate the p85 subunit of 
PI3K, which results in PtdIns(3,4)P2 and PtdIns(3,4,5)P3 synthesis, activation of protein 
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kinase C (PKC), and is linked to Ras and Rho signaling cascades37,38. Eventually Rho family 
GTPases Rac1, CDC42, and RhoA are activated and link Ad5 internalization to actin 
cytoskeleton reorganization, which is required for Ad uptake38,39. Activation of 
macropinocytosis through small Rho family GTPases is another aspect of adenovirus-
mediated integrin signaling and represents a second endocytic pathway controlled by Ad529. 
   
1.1.3 Release of adenoviral particles from endosomal vesicles and intracellular transport 
The fate of cell surface-bound adenovirus particles was studied in detail. Integrin-mediated 
internalization of Ad particles occurred rapidly within 5min at 37°C and was followed by 
vesicle rupture within 15 min post internalization40. Fiber proteins are first dissociated from 
endocytosed virions. Adenovirus endocytosis and penetration in the cytosol are then 
associated with gradual loss of association between hexon and hexon-associated proteins 
(proteins IIIA, VIII, and penton base protein). This in spite of electron microscopic analysis 
that indicates that particles with intact morphology are also released into the cytosol40. The 
internal capsid protein adenovirus cystein protease p23 plays an important role in the 
uncoating of adenovirus particles at the nuclear pore complex through the cleavage of protein 
VI, which links the DNA to hexon41. Degradation of protein VI was only observed after 
interaction of the virus with integrins, though it was dispensable for Ad5 membrane 
penetration during endosome-cytoplasm transition. Indeed, the cytoplasmic tail of integrin β5 
regulates adenovirus-mediated membrane permeabilization and endosomal escape42,43. It 
should be mentioned that αvβ5 interaction with Ad2 penton base alone did not increase 
membrane permeabilization in endocytic vesicles, and thus other viral /host factors could be 
involved (see discussion). Confocal microscopy of Ad5-transduced CHO cells stably 
expressing integrin αvβ3 not only demonstrated enhanced adenovirus endocytosis compared to 
the wild type CHO cells, but also revealed that the β3 subunit colocalized with Ad5 hexon in 
large intracellular vesicles during intracellular traffic and eventually accumulated at the 
nuclear membrane after dissociation from hexon (Fig.2, C.Thirion unpublished results). 
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Fig.2 Colocalization of β3 integrin and hexon protein during intracellular Ad5 transport. 
CHO cells stably expressing αvβ3 integrin were transduced with MOI 1000 Ad5 and stained for β3 integrin and 
hexon protein 15 or 45 minutes after infection44. Confocal microscopy revealed colocalization of hexon and β3 
integrin in large cytoplasmic vesicles 15 minutes post infection. After 45 minutes, most of the β3 integrin was 
localized in proximity to the nuclear membrane, whereas most of the hexon protein was dissociated from β3. 
  
After endocytosis and release into the cytosol, adenovirus particles move towards the nucleus 
in a dynein- and microtubule-mediated way45,46. Tracking of fluorescent adenovirus particles 
(Cy3-Ad) in Ad2-transduced A549 cells revealed that more than 80 % of Cy3-Ad overlapped 
with nuclear DAPI staining within 60 minutes after infection45. Nuclear-localized adenoviral 
particles are further dismantled at the NPC, where they are associated with the nuclear pore 
filament protein CAN/Nup21447. Binding of Ad2 particles to the nuclear envelope occurs in a 
Ran-independent way. Disassembly of bound adenovirus particles at the NPC involves 
histone H1 and nuclear import proteins importin-β and importin-7 47. 
 
 
1.2 Gene therapeutic approaches to treat Duchenne muscular dystrophy (DMD)  
 
1.2.1 Molecular pathology of Duchenne muscular dystrophy (DMD) 
Duchenne muscular dystrophy (DMD) is the most common X-linked lethal disorder, 
occurring in approximately 1 in 3500 male births. Affected children are generally confined to 
a wheelchair by their early teens due to limb muscle weakness, and death usually occurs 
during the third decade of life as a result of either respiratory or cardiac muscle failure. 
Effective treatment is not available. The damage to skeletal and cardiac muscle is caused by a 
deficiency in an essential membrane-associated cytoskeletal protein called dystrophin. This 
dystrophy  results from various mutations (point mutations, deletions) in the dystrophin 
gene48. Deficiency of dystrophin protein in skeletal muscle as well as in other tissues in which 
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isoforms of dystrophin are expressed (brain, retina, and smooth muscle) is the likely cause of 
skeletal muscle wasting, cardiomyopathy, mental retardation, abnormal electroretinograms, 
and gastrointestinal disturbances in DMD patients. Histological features of dystrophic 
muscles reveal necrotic or degenerating muscle fibers at all stages of disease progression. 
Degenerating muscle fibers are often seen in clusters (grouped necrosis) and confined to 
damaged segments of the muscle. These necrotic fibers are subject to phagocytosis, as 
revealed by the presence of infiltrating macrophages and CD4+/CD8+ lymphocytes. In early 
stages of dystrophinopathies active regeneration and replacement of damaged fibers occur. 
The regenerative capacity of the muscle is eventually lost and muscle fibers are gradually 
replaced by adipose and fibrous connective tissue, which results in muscle wasting and 
ultimately muscle weakness49. 
The most-used animal model for DMD is the dystrophin-deficient mdx mouse, which lacks 
expression of full-length dystrophin due to a point mutation in exon 23 of the DMD gene 
generating a premature stop codon that leads to disruption of the dystrophin-associated 
glycoprotein complex (DGC)50,51. One hallmark of DMD and mdx muscle is an increase in 
mechanical-stress-induced permeability of the plasma membrane as demonstrated by dye-
uptake experiments in vivo52. This supports the theory that dystrophic muscle fibers may have 
diminished membrane stability leading to ingress of molecules and ions that are normally 
excluded from the cytoplasm. Additionally, abnormal activity of a leak Ca2+ channel in 
dystrophic muscle fibers was demonstrated, which was activated by calpain protease53,54,55. 
Loss of integrity of the DGC leads to secondary loss of neuronal nitric oxide synthase (nNOS) 
at the membrane and reduced NO production56. Studies in transgenic mice that were either 
deficient for nNOS or overexpressing nNOS, demonstrated that NO production was required 
for attenuation of vasoconstriction in exercising muscle and contributed to alleviation of 
muscle membrane injury by means of an anti-inflammatory mechanism57,58,59. Thus, reduced 
or mislocalized NO production may contribute to DMD pathology through defective 
reversible vasoconstriction following muscle contraction and lack of anti-inflammatory 
response to macrophage action. Moreover, infiltrating T lymphocytes are likely to cause 
progressive fibrosis, as observed in the diaphragm of mdx mice60. The capacity of muscle 
regeneration seems to be impaired in mdx and DMD muscles and eventually fails to keep pace 
with muscle fiber necrosis, resulting in muscle atrophy61,62. The role of satellite cells in 
muscle regeneration in muscular dystrophies has recently been investigated63. A protective 
effect due to reexpression of functional α-DG in regenerating fibers by satellite cells was 
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observed in patients with mild limb girdle dystrophies caused by a primary defect that results 
in aberrant glycosylation of α-DG in mature muscle fibers. This finding implies a 
differentially regulated α-DG glycosylation pathway in satellite cells leading to functional α-
DG expression in regenerating muscle fibers. Expression of functional α-DG in satellite cells 
of a conditional α-DG knockout mouse protected muscle fibers from severe damage 
throughout life64. Since ongoing muscle regeneration in very young DMD patients prevents 
fibrosis, a decrease of the regenerative capacity of satellite cells may be linked to disease 
progression.   
  
1.2.2 Learning about the pathology of muscular dystrophies from mutated proteins of the 
DGC and extracellular matrix  
The dystrophin-associated glycoprotein complex is composed of three subcomplexes: the 
dystroglycan complex, the sarcoglycan:sarcospan complex, and the dystrophin-containing 
complex. Mutations in nearly every member of these complexes are associated with 
dystrophic phenotypes. Interactions between α-dystroglycan (α-DG) and the cytoplasmic 
globular domains of laminin α1 and α2 establish the link between the DGC and the 
extracellular matrix65,66. The importance of this link for muscle fiber integrity was 
demonstrated by loss-of-function mutations that resulted in severe congenital (laminin α2-
chain) and Duchenne muscular dystrophies (dystrophin). Loss-of-function mutations within 
α-DG are lethal due to developmental defects in membrane formation. The lectin-type 
interaction between laminin alpha-2 chain and α-DG is affected by altered glycosylation of α-
DG67. Accordingly, mutations within glycotransferases that modify α-DG (Fukutin, Fukutin-
related protein, LARGE, POMT1, POMGnT1) lead to abnormal glycosylation, impaired 
interaction with laminin-2, and are associated with muscular dystrophies68,69,70.  
Another binding partner of laminin-2 is α7β1 integrin, linking the cortical actin filaments to 
the basal membrane via α-actinin71. Likewise, mutations in the α7 integrin gene are associated 
with muscular dystrophies in humans72. The sarcoglycan protein family is composed of 6 
transmembrane glycoproteins (α,β,γ,δ,ε,ζ) which form a complex at the plasma 
membrane. Τhe sarcoglycan complex is tightly bound to β-dystroglycan via δ-sarcoglycan73. 
Mutations in sarcoglycan genes are the primary genetic defects in some forms of human 
autosomal-recessive limb-girdle muscular dystrophy (LGMD2C-F), leading to disruption of 
the sarcoglycan-sarcospan complex. The α-sarcoglycan subunit of the sarcoglycan complex is 
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exclusively expressed in skeletal muscle and is replaced by ε-SG in other tissues74. 
Knowledge of the existence of ε-SG-containing sarcoglycan-sarcospan complexes in smooth 
and heart muscle explains the cardiomyopathic phenotype in β-, and δ-SG deficient mice, 
which is absent in α-SG knockout mice75,76. The syntrophin family of proteins is a component 
of the DGC binding directly to dystrophin. Syntrophins share similar protein domain 
structures consisting of a PH domain, PDZ domain, two coiled-coiled (CC) modules and 
unique syntrophin C-terminal regions. Syntrophins interact with a number of proteins 
including dystrobrevin, nNOS, ErbB4 receptor tyrosine kinase, voltage-gated Na+ channel, 
stress-activated protein kinase-3 (SAPK), and phosphatidylinositol-4,5-bisphosphate 
(reviewed in77,78). 
As demonstrated by the role of NO-signaling in reversal of vasoconstriction, signaling 
through cytosolic DGC-associated proteins may be important for muscle function and 
survival. Insights into the complex molecular muscle pathology of DMD helped to identify 
molecular targets for therapy and to design experimental gene therapy approaches. 
 
1.2.3 Molecular and gene therapy approaches to treat muscular dystrophies.   
The dystrophin paralog protein, utrophin, shares most of the dystrophin functions, including 
binding to β-dystroglycan and β-actin and interacting with α-synthrophin. Despite its 
similarity to dystrophin, utrophin displays a different localization in normal muscle, where it 
is confined to the neuromuscular and myotendinous junctions78. The hypothesis that utrophin 
may substitute for dystrophin function in dystrophin-deficiency was tested by generating 
transgenic lines of mdx mice overexpressing utrophin under the control of a muscle-specific 
muscle creatine kinase (MCK) promoter79. Indeed, utrophin expression was observed 
throughout the sarcolemma and alleviation of muscle pathology, including calcium 
homeostasis, membrane permeability, correct assembly of DGC at the sarcolemma, and force 
generation was observed79,80. 
Permanent gene therapy of DMD by direct dystrophin/utrophin transfer represents the therapy 
of choice. Due to the large size of dystrophin cDNA (14kb), gene transfer vectors with large 
packaging capacity must be used e.g., herpes simplex-based vectors, high-capacity adenovirus 
(hc-Ad), and plasmid DNA vectors). Accordingly, hc-Ad-mediated dystrophin transfer in mdx 
mice resulted in sustained long-term expression of dystrophin and improvement in muscle 
function one year after the gene transfer81,82. Similarly, transfer of the non-immunogenic 
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utrophin led to mitigation of the dystrophic phenotype and improvement in muscle function83. 
Surprisingly, extrasynaptic utrophin localization with therapeutic effect in mdx mice was 
encountered after muscle-specific overexpression of cytotoxic T-cell N-acetylgalactose 
transferase (CT-GalNAc)84. CT-GalNAc was shown to specifically transfer β−1,4-GalNAc to 
synaptic α-DG and has been proposed to influence alternative dystroglycan proteolysis and 
eventually leading to extrasynaptic accumulation of CT-modified α-DG and sarcolemmal 
utrophin association85.  Alpha 7 integrin was overexpressed in the intention of compensating 
for the loss of sarcolemma membrane stability via additional α7 integrin - laminin α2 chain 
interactions, and led to a partial amelioration of the dystrophic phenotype in mdx/utr (-/-) 
mice86.  
Due to the fact that most frame-shift-causing mutations in DMD are located within the 
spectrin-like rod domain, and partial in-frame deletions of this domain are associated with a 
milder phenotype in Becker muscular dystrophy (BMD), antisense oligoribonucleotide-based 
therapy was considered87,88. Masking of critical splice sites on pre-mRNA with RNAseH-
resistant 2-O-methylated phosphothionated antisense oligoribonucleotides (2OMeAO)88 led to 
expression of functional dystrophin in the mdx mouse by promoting skipping of the mutated 
exon89,90,91,92. In a recent report Barton-Davis et al. used the stop codon read-through activity 
of aminoglycoside antibiotics to restore dystrophin-expression in mdx mice93. Although the 
read-through of stop codons by aminoglycoside antibiotics was successful in vitro94, the 
positive effect of gentamycin that was reported in mdx mice was neither reproducible in other 
laboratories nor in humans by other investigators95,96.  
Overexpression of NO in transgenic mdx mice reduced inflammation and membrane 
damage59. This result supports the theory that loss of membrane NOS contributes to muscle 
pathology in mdx mice.  Indeed, reduction of inflammation with corticosteroids prednisone 
and deflazacort increases muscle strengths in some patients and is a partially effective therapy 
for DMD97,98. 
In 1989, Partridge et al. demonstrated that transplantation of myogenic precursor C2C12 cells 
into dystrophic muscles of mdx mice led to dystrophin expression and phenotypic correction 
of dystrophin-positive fibers99. Unfortunately these results could not be expanded to 
transplanted myoblasts in DMD patients, which poorly survived and had an impaired 
proliferative capacity ex vivo100,101. Recently, bone-marrow-derived stem cells and a 
specialized class of vessel-associated foetal stem cells termed mesoangioblasts were 
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transplanted into mdx mice and led to the restoration of dystrophin and α-sarcoglycan 
expression in dystrophic muscles102,103. Sampaolesi et al., transferred a copy of α-SG using a 
lentiviral vector in autologous mesoangioblasts, expanded this cells in vitro and reinjected 
these cells into the femoral artery of α-SG null mice. Intra-arterial delivery of corrected 
mesoangioblasts resulted in morphologic and functional correction of all downstream 
muscles103. Nonetheless correction of autologous stem cells for cell therapy of DMD with 
full-lengths dystrophin cDNA will require a stably integrating vector with large insertion 
capacity.    
 
1.2.4 Vectors for gene therapy 
Great efforts have been undertaken to develop a gene-replacement therapy by introducing a 
functional copy of the affected gene back into the target organ. Vectors for gene delivery can 
be divided into non-viral plasmid-based DNA vectors and viral vectors, including AAV, AdV, 
HSV-1, Retro- and Lentiviral vectors. Typically, 106 plasmid copies are needed to transfect a 
single cell resulting in 102-104 nuclear copies104,105, whereas up to 5% of applied adenoviral 
genomes can be detected in cells 48h post-transfection with only 103 transducing vector 
genomes used per cell (see chapter 3.1.4). The low transduction efficiency observed with 
plasmid DNA vectors is due to the numerous hurdles encountered by naked DNA-based 
vectors during the transduction process. Degradation by serum and cytosolic nuclease activity, 
cellular association of DNA complexes, lack of specific internalization, inefficient endosomal 
escape, or low intracellular diffusion of large DNA molecules has to be overcome for efficient 
delivery. However, solutions for these problems are currently developed to facilitate gene 
delivery in vivo106,107,108,109. One way to overcome these hurdles is to transfer functional 
properties of viruses to non-viral vectors, and by doing so, exploiting the cellular machinery 
by an effective gene delivery. DNA polyplexes are comprised of cationic peptides or 
polymers with DNA-condensing capacity to which functional ligands are covalently attached. 
These “artificial viruses” have been successfully used in vivo for targeted gene transfer, and 
may be equivalent to virus-based vectors in the future110. 
Viruses, on the other hand have developed mechanisms to exploit the cellular machinery to 
gain access and efficiently deliver their genomes into the nucleus. The five main classes of 
viral vectors can be divided in strictly integrating vectors (oncoretroviruses, lentiviruses) and 
episomally maintained vectors (AAV, adenoviruses, HSV-1). Most oncoretroviruses are based 
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on Moloney murine leukaemia virus (MLV) and have recently been used to cure patients 
suffering from severe immunodeficiency (SCID)-XI disease following transduction of 
autologous hematopoietic stem cells ex vivo111. Unfortunately, the inherent risk of insertional 
mutagenesis that is associated with oncoretroviruses is a serious concern, since two out of the 
11 patients treated developed a leukemia-like syndrome that arose from retrovirus insertion 
into the LMO2 oncogene region112. Besides being potentially oncogenic, MLV-type 
retroviruses require cell division to gain access to the nucleus, and thus transduction is limited 
to dividing cells. In contrast to oncoretroviruses, lentivirus vectors are able to penetrate a 
nuclear membrane and transduce non-dividing cells. Most lentiviral vectors are HIV-derived, 
though they retain only minimal parts of the parental genome (<5%). Lentiviral vectors are 
able to generate long-term gene expression without inflammation and have been successfully 
used for gene therapy of CNS disorders like Parkinson’s disease113,114. Both oncoretrovirus- 
and lentivirus-based vectors have an inherent oncogenic potential due to insertional 
mutagenesis.  
 
Table1 
Vector type 
Vector 
Genome   
Packaging 
capacity Tropism 
Acute 
Inflammation 
Genomic 
 ntegration 
Application 
Limitations 
Vector advantages 
 
Retrovirus 
 
RNA 
 
8kb 
 
Diving cells 
only 
 
Low 
 
Integration  
 
1.Transduction limited to 
diving cells 
2.Insertional mutagenesis 
 
Persistent gene 
expression 
Lentivirus RNA 8kb Broad Low Integration  1.Insertional mutagenesis Persistent gene 
expression 
HSV-1 
 
 
dsDNA 40-150kb Neuronal  High Episomal 1. Acute inflammation 1. Large packaging 
capacity 
2. Neuronal cell tropism 
AAV ssDNA 4.8kb Broad  Low Episomal; 
Integration 
(<10%)  
1.Small packaging 
capacity 
2. Integration in 
transcriptionally active 
genes  
1. Non-inflammatory 
2. Non-pathogenic 
 
Adenovirus dsDNA 8kb-
36kb* 
Broad High Episomal 1. Inflammation (capsid-
mediated) 
1. Efficient transduction  
2. High packaging 
capacity 
 
Table1. Main characteristics of the currently used viral vectors for gene therapy. *High capacity adenoviral vectors devoid 
of all viral genes with a maximum packaging capacity of 36kb. 
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Site-directed integration of vector genomes into the host genome would therefore be a break 
through in gene therapy and make treatment safer and regulatory approval more probable.  
A small proportion of wild type adeno-associated virus 2 (AAV2) is able to integrate into a 
specific site in HeLa cells on chromosome 19, which is called AAVS1. The majority of 
AAV2, however, tends to integrate into multiple sites and active genes of hepatocytes in 
vivo115,116. One particularly beneficial feature of AAV vectors is the lack of acute 
inflammatory response after gene transfer and its natural tropism for skeletal muscle, which 
makes AAV a good candidate for muscle-directed gene therapy117,118. Major limitations of 
AAV vectors are the small packaging capacity of 4.8 kb and conversion of the single-stranded 
into a double-stranded DNA genome. Solutions for both problems are currently being 
developed through the construction of ds hairpin AAVs and splitting of expression cassettes, 
which can be reconstituted by splicing between linear concatemeric AAV genomes119,120.  
Adenoviruses are the most efficient class of vectors in terms of gene delivery to the nucleus 
and will be presented in detail in the next chapter. The main features of the currently used 
viral vectors for gene therapy are summarized in Table 1. 
 
1.3 Adenoviral vectors for gene therapy 
 
Adenoviruses are non-enveloped DNA viruses carrying a linear double-stranded genome. To 
date 51 human serotypes have been identified and classified into 6 subgroups (A to F)1. The 
history of adenovirus vectors in gene therapy is incontestably marked by the death of Jesse 
Gelsinger, who took part in a gene therapy trial for ornithine transcarbamylase (OTC) 
replacement therapy at the University of Pennsylvania in Philadelphia. After receiving the 
highest dose of vector in the trial (3.8x1013 particles) he developed symptoms of liver injury 
and disseminated intravascular coagulation, eventually leading to multiorgan failure and 
death121. The fatal course of the treatment was directly related to an acute inflammatory 
response to the injected adenoviral vector. The vector used in this trial was a first-generation 
adenovirus with deleted early genes (E1 and E3). Indeed, the initial response to 
intravascularly administered Ad vectors occurs within minutes and can be attributed to the 
innate response. A detailed evaluation of risks and side effects following the application of 
first-generation adenoviruses in clinical human trials was reported in a special issue of Human 
Gene therapy122.  
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 1.3.1 Immunological barriers to adenovirus gene therapy  
Adenovirus capsid is able to directly activate antigen-presenting cells (e.g., dendritic cells, 
macrophages), and triggers the release of proinflammatory cytokines123,124,125. Adenoviruses 
have therefore been extensively engineered to reduce their immonogenicity. Second-
generation vectors having E1, E2 and E4 gene deletions, as well as third-generation vectors 
that are devoid of all viral genes, both show reduced immunogenicity. Third generation 
vectors can accommodate large DNA fragments up to 36 kb, and allow for prolonged 
transgene expression in vivo due to decreased acute and chronic toxicity126,127,128,129,130. 
Despite a strong stimulating action of first-generation vectors on the innate immune system, 
efficient local application is possible, which may be particularly suited for applications 
requiring only transient gene expression. The brain is an organ where the innate immune 
system can be investigated in isolation from the acquired immune system. Infiltration of 
peripheral T lymphocytes into the brain only occurs if priming of the peripheral immune 
system has previously taken place and signs of acute brain inflammation related to the same 
group of antigens are established131. The observed immune response to adenovirus-transduced 
brain cells after peripheral immunization (with adenovirus) is due to an anti-Ad genome 
immune response, that is partly directed against leakily expressed adenovirus genes and the 
transgene itself132. In agreement with this model, gene transfer in the brain using a third 
generation adenovirus was not associated with long-term brain inflammation and no loss of 
transgene expression occurred after peripheral immunization with adenovirus (the vector used 
for peripheral immunization shared the same Ad backbone but lacked the corresponding 
transgene expression cassette)129. Acute adenovirus-mediated vector cytotoxicity is a dose-
dependent phenomenon that contributes to the loss of transgene expression in transduced 
tissues upon injection of >108 infectious particles133. One major goal for vector development 
is therefore to decrease the required vector dose. Preexisting anti-virus immunity is another 
hurdle for adenovirus gene therapy preventing vector readministration. In humans the extent 
of the humoral response is dependent upon preexisting antibody titers and the route of 
administration134,135. However, another serious concern is the generation of an antibody-
mediated immune response to transgenes, especially if the antigen is to be secreted. In this 
case generation of humoral anti-transgene response depends upon expression of the transgene 
in antigen-presenting cells. This can be avoided if tissue-specific promoters are used to limit 
transgene expression to non-hematopoietic tissues136,137. Preexisting humoral immunity can be 
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evaded by using tropism-modified viral vectors, which are able to circumvent anti-fiber 
neutralizing antibodies present in ascites fluid138. In an alternative strategy used to circumvent 
neutralizing antibodies, adenoviral particles were coated with a multivalent polymer capable 
of shielding viral epitopes from neutralizing antibodies and achieving good gene transfer 
efficiency in vivo139. In another approach designed to circumvent preexisting anti-Ad5 
immunity, non-Ad5-based adenoviral vectors were used to infect cells in vitro140. Likewise, 
sequential administration of two different adenovirus serotype vectors “sero-switching“ 
allowed for repeated transgene expression even if the vectors belonged to the same 
subgroup141,142. Transduction of dendritic cells by adenovirus plays a central role for the 
induction of anti-adenovirus-directed immunity. Transgene expression in non-target tissues 
can be avoided by targeting gene expression, either transcriptionally through the use of tissue-
specific promoters, or transductionally by redirecting attachment of viral vectors to tissue-
specific receptors. Expression of transgenes under control of the muscle creatine kinase 
promoter (MCK) led to stable long-term expression of transgenes in muscle after adenovirus-
mediated gene transfer143,144,145,146. Similarly, use of liver-specific promoters allowed for 
adenovirus-mediated long-term expression of apolipoprotein A-I in hepatocytes of 
immunocompetent mice137. 
 
1.3.2 Maturation-dependent decrease in adenovirus transduction of skeletal muscle 
A major hurdle for gene transfer to skeletal muscle was revealed with gene-transfer 
experiments in animals of different ages. Transduction efficiency was linked to the maturation 
state of the muscle. Whereas skeletal muscle fibers of newborn mice were efficiently 
transduced by adenovirus, mature muscle fibers of adult mice were only poorly transduced147. 
This maturation-dependent decrease in transduction of mouse skeletal muscle in vivo was 
mirrored in vitro by the decrease in transducibility of cultured human myotubes as compared 
to myoblasts. In contrast, adenoviral transduction of regenerating and dystrophic muscle 
fibers of adult dystrophin-deficient mdx and merosin-deficient dy/dy mice was higher than that 
of normal muscle fibers, although still considerably lower than in neonate muscle148,149. 
 
1.3.3 Expression level of CAR is crucial for transduction of skeletal muscle by adenovirus in 
vivo  
The high adenoviral transduction of newborn myofibers may be partly due to transduction of 
myoblasts and partly to the higher levels of CAR present in these myofibers150. Moreover, in 
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adult mice, the low expression levels of the primary virus-attachment receptor CAR, in 
conjunction with the decrease of secondary internalization receptors, integrins αvβ3 and αvβ5, 
may account for the low transducibility of skeletal muscle in vivo151,152. However, CAR 
expression is upregulated on the surface of regenerating myofibers in mdx mouse muscles. A 
similar increase in CAR levels has been observed in regenerating fibers of human 
inflammatory and degenerative muscle disorders153, suggesting that these fibers may also be 
susceptible to adenoviral transduction.  
Therefore, several strategies based on the augmentation of CAR molecules on the cell surface 
that enable increased transduction efficiency and adenovirus-mediated gene transfer in adult 
myofibers have been developed. Sequential administration of hCAR- and EGFP-encoding 
AdV have allowed for repetitive and efficient transduction of young adult myofibers154. In 
order to evaluate how overexpression of CAR in muscle may affect adenovirus-mediated gene 
transfer into mature skeletal muscle, transgenic mice expressing the CAR cDNA under 
control of a muscle-specific creatine kinase (MCK) promoter were generated155. In adult CAR 
transgenic mice (CAR-Tg) the susceptibility of skeletal muscle to adenovirus transduction 
was significantly higher than in non-transgenic littermates. After a single injection of 2x1010 
particles adenovirus carrying a β-galactosidase reporter gene in tibialis anterior muscle of 
adult animals, the transgene was expressed in 433 ± 121 muscle fibers of CAR-Tg mice vs. 8 
± 4 fibers in non-transgenic controls. A single AdV injection may lead to the transduction of 
the entire tibialis anterior and extensor digitorum longus (EDL) muscle155. This study 
demonstrated that (i) upregulation of the primary adenovirus receptor CAR in myofibers 
confers a high susceptibility to adenovirus-mediated gene transfer in vivo, and (ii) that low 
expression of CAR in adult skeletal muscle is a major impediment to efficient adenoviral 
transduction. Recent studies using an experimental histone H3 deacetylase inhibitor 
FR901228 showed that this compound upregulated CAR and alpha v integrins and enhanced 
adenovirus gene transfer into CD34+ cells by 10-fold156. The use of this compound in 
adenovirus-mediated gene transfer experiments to skeletal muscle is currently being explored  
 
1.3.4 The extracellular matrix may act as a physical barrier to adenovirus in vivo 
A further explanation for the poor transducibility of adult skeletal muscle may be the presence 
of the extracellular matrix itself, which may constitute a physical barrier for large viral 
particles. The average pore size of the extracellular matrix has been estimated to be 40 nm157. 
Indeed, large herpes simplex viral vectors (HSV-1) are unable to penetrate and transduce 
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mature myofibers when injected directly into skeletal muscle158. Since adenovirus particles 
have a diameter of 60-85 nm, depending on the fiber length of different adenovirus serotypes, 
a physical inhibition of myofiber transduction by the myofiber basal lamina may not be ruled 
out completely. 
In addition to low efficient AdV-mediated gene transfer to adult skeletal muscle, several 
obstacles have been encountered in in vivo experimentation in different animal models for 
muscular dystrophy. These limitations, in particular systemic dissemination of the vector and 
immunologic reactions of the host, need to be overcome before therapeutic use of AdV in 
human muscular dystrophy can be considered. To prevent major muscle degradation in the 
mdx mouse, 30 to 40 % of the normal level of dystrophin must be expressed in an even 
distribution throughout the muscle159,160. The route of vector administration determines the 
biodistribution and transduction efficiency of tissues161. After intramuscular vector injection, 
transgene expression is found only within a restricted area near the injection site and in the 
vicinity of the encoding myonucleus162,163. The muscle fascicles as well as the connective 
tissue may function as barriers for the spread of viral vectors within the muscle after 
intramuscular injections. Intravascular delivery of plasmid DNA vectors with increased 
pressure to limbs of monkeys resulted in transgene expression in all limb muscles without 
notable toxic side effects164. Histamine-induced endothelial permeabilization allowed for a 
similarly widespread expression in hind-limb muscles after intraarterial injection of 
recombinant adeno-associated virus118. Likewise, AdV can egress out of the intravascular 
compartment if increased hydrostatic and decreased osmotic pressure is applied165. Tissue 
targeting may be even more essential for systemic delivery of gene-transfer vectors than it is 
for local administration. 
 
1.4 Targeting of viral vectors for gene therapy 
  
To render the binding properties of the gene-transfer vectors tissue-specific, targeted viral 
vectors with modified binding properties are currently being developed. As discussed above, 
targeted viral vectors are likely to be less immunogenic, less toxic and safer, and may 
eventually allow a systemic application of the vector. Retargeting of viral vectors has been 
achieved for several viruses including retrovirus, adenovirus, and adeno-associated virus 
166,167,168,169. Targeting adenovirus requires a two step approach involving (i) ablation of the 
native tropism, and (ii) introduction of a novel targeting moiety. Several strategies based on 
 
 
the augmentation of CAR molecules on the cell surface, direct targeting of adenoviral 
particles through genetic engineering of the fiber and capsid proteins, and compound-
mediated retargeting of AdV have been developed to enhance gene delivery to target tissues 
(Fig.3). 
 
 
Fig.3 Strategies for adenovirus targeting and enhanced gene delivery into the targeted tissues. 
Increase of CAR expression on the target tissue surface (I), direct targeting of adenoviral particles through 
genetic engineering, including insertion of targeting ligand into the HI-loop, addition of C-terminal  targeting 
ligands, fiber-swap between Ad-serotypes,  or genetic engineering of the capsid proteins (II)  and compound-
mediated retargeting of AdV through attachment of bispecific protein- or antibody-adapters (III) are currently 
being tested for adenovirus retargeting. 
 
 
 
1.4.1 Ablation of the native tropism 
The development of a tissue-specific viral vector for gene therapy necessitates an 
understanding of the molecular process and the ability to manipulation virus-cell interactions. 
The solved crystal structure of adenovirus type 12 fiber knob and its cellular receptor CAR 
was the first step towards a rational design of retargeted vectors. The CAR-binding interface 
of Ad12 knob is formed by four loop regions of Ad12 knob that interact with a single face on 
the N-terminal domain of human CAR (CAR-D1) (Fig.4).  
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Fig.4 Ribbon diagram of the Ad12 knob-CAR D1 complex viewed down the viral fiber. 
The core of each knob monomer is composed of an eight-stranded antiparallel beta sandwich. The V sheet is 
colored purple and the R sheet including the HI loop are blue. The AB loop is highlighted in yellow, and all other 
regions are grey. The CAR D1 domain is colored in turquoise. In Ad12 knob the interfacial residues are D415, 
P415, P418, I426 (AB loop), V450, K451 (CD loop), and Q487, Q494, S497, and V498 (E and F strands) for one 
knob monomer and P517, P519, N520, and E523 (FG loop) for the adjacent knob molecule. The figure was 
kindly provided by Paul Freimuth and John Flanagan with reprint permission from Science magazine19. 
 
 
The interacting region is constituted by the AB loop, the C-terminus of  the DE loop, the short 
F strand, and the FG loop on the adjacent knob monomer (Fig.4)170. Sequence analysis of the 
fiber knobs of different Ad serotypes led to the identification of residues critical for CAR-Ad5 
knob interaction171,172. The point muations S408E, K417G (AB loop), K420A (B sheet), 
L485K (beta strand F), and Y477A (DE loop) have been found to be very effective in ablating 
CAR-knob interactions171,172,173. Likewise, introduction of the double K417I + K420I double 
point mutations effectively ablated CAR binding174. 
However, the in vivo tissue-distribution of systemically applied CAR-ablated viruses was 
unchanged after intravenous AdV administration, in contrast to detargeting mutations in the 
putative HSG-binding motif contained within the Ad5 shaft, which reduced the hepatic gene 
transfer in vivo175,176. The investigation of the blood clearence rate of adenovirus 
demonstrated that 99.9 % of the circulating virus was removed within the first hour with a 
half life of less than 2 minutes177. Tissue macrophages like liver Kupffer cells are likely to 
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sequester adenovirus via a CAR-independent entry mechanism, which may involve 
opsonizing serum factors  and occur directly through integrins of the αv or αMβ2 type178,179. 
Indeed, depletion of Kupffer cells led to increased gene transfer of AAT-1 to liver without 
generating an anti-AAT1 humoral immune response180. Likewise, since monocyte-derived 
dendritic cells (DC) do not express CAR, ablation of binding to CAR is not likely to influence 
DC transduction, and hence adenoviruses defective for CAR-binding may not reduce the DC-
mediated immune-response after AdV gene transfer181. It was further shown that efficient 
ablation of the native tropism required simultaneous removal of CAR and integrin 
interactions182. 
 
1.4.2 Genetic modifications of the adenovirus fiber protein 
Modification of the adenovirus tropism can be achieved through genetic modification of the 
fiber protein by the addition of targeting ligands to the C-terminus183,184,185,186. Limited 
enhancement of the transduction of myofibers and glioma cells was achieved in vivo using an 
extended tropism vector with a C-terminal poly-lysine modification (20 residues added)187. 
However, C-terminal additions to the fiber seem to be restricted to small ligands, since the 
addition of 27 amino acids prevented trimerization of the fiber protein184,185,188.  
The HI-loop of the fiber protein seems better suited as an insertion site for targeting ligands. 
Proof-of-principle was demonstrated upon insertion of a FLAG octapeptide189. Similarly, the 
insertion of poly-lysine and RGD-peptides into the HI-loop led to increased transduction of 
cell lines in vitro190. Insertion of small targeting peptides into the HI loop, e.g., selected by 
phage display, is an effective way to retarget adenovirus. Nicklin et al. combined CAR-
ablation with insertion of a cell-specific ligand selected by phage display and achieved 
selective transduction of endothelial cells191.  
Since hc-Ad vectors display an enhanced safety profile and reduced toxicity, retargeting of 
hc-Ad constitutes a logical step towards a clinical application of AdVs. Retargeting of hc-Ad 
by incorporating RGD-4C peptides into the HI loop was reported192.  
The generation of fiber chimeras, which transfer parts of the Ad serotype-specific tropism 
from one virus to the other, represents another possibility to genetically alter the adenovirus 
tropism193,194,195. Multitudes of serotype-specific tropisms provide a considerable natural 
reservoir for tissue-specific retargeting of Ad5. The chimeric vector Ad5.F35, which contains 
the Ad35 fiber in the Ad5 capsid, efficiently transduced CD34+ cells in an αv-integrin 
independent manner196. Likewise, transduction of smooth muscle cells was enhanced with 
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Ad5.F16 fiber-chimeric adenovirus303. Removal of the entire fiber knob represents a more 
drastic modification to retarget adenovirus. Targeting ligands are added as C-terminal 
extensions to trimerization-promoting domains derived from T4 phage protein fibritin, 
MoMuLV envelope glycoprotein, or neck region peptide of human lung surfactant protein D, 
which are fused to 7 fiber shaft repeats197,198,199. Gene transfer into CAR-negative, but αvβ3/5 
integrin-positive human embryonal rhabdomyosarcoma (RD) cells with knobless retargeted 
adenovirus resulted in a 10-fold higher transduction with the modified vector as compared to 
with unmodified Ad5198. Attempts to fuse the immunoglobulin-binding triple-helix bundle 
scaffold Z, which is derived from domain B of Staphylococcal protein A, to knobless 
adenovirus particles failed200. However, other ligands that fold independently from disulfide 
bridge-formation have been successfully fused to knobless adenovirus particles201,202.  In 
addition to genetic retargeting via modifications of the Ad fiber protein, targeting ligands have 
been successfully added to adenovirus hexon, penton base, and protein IX203,204,205. Protein IX 
fusions can be of considerable length, as demonstrated by the rescue of adenovirus that 
displays a protein IX-EGFP C-terminal fusion protein206.  
 
1.4.3 Compound targeting vectors 
Adaptor-mediated retargeting entails the conjugation of an anti-adenovirus antibody with a 
targeting ligand. Redirecting AdV to the folate receptor validated this concept207. Using 
similar approaches, AdV has been targeted to multiple receptors including αv integrin, FGF2, 
EGFR, CD105, CD3, E-selectin, CD40, and β1-integrin. These retargeted adenoviruses 
significantly enhanced the specificity of viral infection in vitro208,209,210,211,212,213. Moreover, 
these results clearly demonstrate that cell lines refractory to infection may efficiently be 
transduced with retargeted AdV, and internalization of Ad vectors by cells that lack αv 
integrins can be achieved through targeting cytokine/growth factor receptors214. Studies in 
vivo indicate that adenovirus-conjugate complexes are stable and provide for increased target 
cell transduction and decreased liver toxicity215. Markedly increased transduction of target 
tissues, longer residence time in the circulatory system, lower systemic toxicity with absence 
of liver necrosis, and in vivo therapeutic benefit have been observed216,217,218. Although these 
results are encouraging, after systemic administration most AdV particles are still found in the 
liver and the secondary target organs (lung, heart, spleen). When administered locally, 
fibroblast growth factor receptor-retargeted Ad5 is able to transduce tumor cells more 
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efficiently than non-targeted vectors216. EGFR-targeted adenoviruses are particularly useful 
for transduction of tissues with low expression of alpha v integrins, since the internalization of 
EGFR-bound Ads occurs via internalization of the EGF receptor211. Reynolds et al. reported a 
highly efficient double-targeting approach in which a tissue-specific promoter controlled 
transgene expression, ‘transcriptional targeting’, and was combined with antibody-mediated 
retargeting of adenovirus to a pulmonary endothelial marker, ‘transductional targeting’219. In 
this case, 30 times more transgene expression was detected in the targeted tissue after 
systemic vector administration (compared to liver), which was equivalent to a 10000-fold 
reduced transgene expression in the liver as compared to a conventional non-targeted vector. 
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2. Material and methods 
 
2.1 Primary cells and cell lines 
2.1.1 Culture conditions for established cell lines  
293A cells, CV-1 cells, and rat L6 myoblasts were grown in Dulbecco´s modified Eagle 
medium (DMEM) supplemented with 10% fetal calf serum (FCS) (Invitrogen Life 
Technologies, Karlsruhe, Germany) in a humidified atmosphere with 5% CO2 at 37°C. 
N52.E6 cells221 were grown in alpha MEM (Invitrogen Life Technologies, Karlsruhe, 
Germany) containing 10 % FCS in a humidified atmosphere with 5% CO2 at 37°C. CHO cells 
expressing integrin alpha v beta 3 (CHOαvβ3) were kindly provided by Dr. Gawaz 
(Medizinische Klinik, Klinikum rechts der Isar und Deutsches Herzzentrum, Technische 
Universität München, Germany). CHOαvβ3 cells were cultured in Ham’s F10 medium 
(Invitrogen Life Technologies, Karlsruhe, Germany) containing 10 % FCS in a humidified 
atmosphere with 5% CO2 at 37°C. 
 
2.1.2 Culture conditions for primary cells  
Primary human, ape, pig and mouse myoblasts were obtained from the Muscle Tissue Culture 
Collection, Friedrich-Baur-Institut (Munich, Germany). Primary uman, ape and pig cells were 
grown in skeletal muscle cell growth medium supplemented with 5% FBS in a humidified 
chamber with 5% CO2 at 37°C (Promocell, Heidelberg, Germany). Primary mouse myoblasts 
were grown in Quantum 212 medium (PAA laboratories, Pasching, Austria) in a humidified 
atmosphere with 5% CO2 at 37°C. Human umbilical vein endothelial cells (HUVEC) were 
kindly provided by A. Herrmann (Cardion AG, Erkrath, Germany) and were grown in M199 
medium with 60 mg/l ECGS (epidermal cell growth substrate), 100 mg/l Heparin (both from 
Sigma, Deisenhofen, Germany), 20% FBS and penicillin-streptomycin. HUVECs were used 
at passage 3 and 4. 
Specimens of human saphenous vein were obtained from patients undergoing aortocoronary 
bypass surgery with approval by the local ethics committee and informed consent of the 
patients, and vascular smooth muscle cells isolated using the explant technique220. Cells were 
grown in DMEM supplemented with 15% fetal calf serum, 100 µg/ml streptomycin, 100 U/ml 
penicillin, 1.9 mmol/L L-glutamine, 9.6 mmol/L sodium pyruvate and non-essential amino 
acids (all reagents were purchased from Invitrogen Life Technologies, Karlsruhe, Germany) 
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in a humidified atmosphere with 5% CO2 at 37°C. For transfection experiments subconfluent 
cells in 24-well-plates were used. 
 
2.1.3 Enrichment of myoblasts with magnetic cell sorting MACS 
Primary human myoblasts were separated from co-purified fibroblasts by means of MACS. 
Myoblasts (1x106 cells) were cultured in a 10cm cell culture dish and detached by trypsination 
(treatment with 0.25% trypsine and 1mM EDTA (reagents from Sigma, Deisenhofen, 
Germany) for a maximum of 2 min at 37°C followed by centrifugation (200 x g, 5 min). Cells 
were resuspended in 1ml MACS buffer (PBS supplemented with 0.5% BSA) and incubated 
for 45min on ice with purified 3µg/ml anti-NCAM antibody 5.1H11. Cells were washed 3 
times, resuspended in 80µl MACS buffer, and 20µl of rat anti-mouse IgG1 micro beads 
added, and incubated for 30 min on ice (Miltenyi Biotech GmbH, Bergisch Gladbach, 
Germany). Cells were washed again in MACS buffer, resuspended in 0.5ml MACS buffer and 
loaded onto the pre-equilibrated MACS column placed in the magnetic column holder. Non-
labeled cells passed the column and were discarded. Bound cells were eluted directly in SGM 
medium from the column outside the column holder in 1ml MACS buffer.  
 
2.1.4 Isolation and differentiation of primary monocyte-derived dendritic cells 
Monocyte-derived dendritic cells were obtained by differentiation of monocytes isolated from 
primary peripheral blood lymphocytes (PBLs) by MACS enrichment of CD14+ cells. 
Heparinated blood (Heparin from Sigma) was collected and 20 ml Ficoll (Pancoll human, 
density 1.077g/ml from Pan Biotech GmbH, Aidenbach, Germany) overlaid with 30ml blood 
per Falcon (50ml). Following centrifugation (2000rpm, 30min, RT, without brake) the 
interphase containing PBLs was removed and transferred into a new falcon and mixed 1:1 
with PBS. After centrifugation (1900 rpm, 10 min, RT) the cell pellet was resuspended in 50 
ml PBS and once again centrifuged (1900 rpm, 10 min, RT). Next, the cell pellet was 
resuspended in MACS buffer (80µl per 1x107 cells) and 15µl anti-CD14 magnet beads added 
per 1x107 cells. MACS separation was done as described above and cells grown in dendritic 
cell differentiation medium (DC medium). Monocytes were cultured for 7 days in DC 
medium and immature DCs characterized by FACS for surface expression of DC-specific 
markers CD11c, DC-SIGN, and CD86. DC medium contained X-Vivo 15 growth medium 
(2ml per 3x106 cells) supplemented with GM-CSF 800U/ml and IL4 800U/ml cells 
(BioWhittaker, Walkersville, USA).  
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2.1.5 Growth conditions for hybridoma cells, adaptation to serum-free conditions, and 
purification of monoclonal antibodies 
5.1H11 hybridoma cells were cultured in DMEM supplemented with 10% FCS, 2mM 
glutamine, 0.1mM non-essential amino acids, and 1mM sodium pyruvate. Production of 
hybridoma supernatant in serum-free Hybridoma-SFM (Invitrogen Life Technologies, 
Karlsruhe, Germany) was done by direct adaptation of 5.1H11 cells to hybridoma-SFM 
medium. Serum-containing medium was removed from 5.1H11 cells and only semi-adherent 
cells, which are 100% viable, overlaid with hybridoma-SFM medium. Supernatant was 
collected after 48h and antibodies affinity-purified with protein G. Briefly, supernatant was 
diluted 1:4 in equilibration buffer (20mM sodium phosphate pH 7.0) and passed through a 
protein G column (Roche Diagnostics GmbH, Mannheim, Germany). Unbound material was 
washed from the column with 50ml washing buffer (washing buffer: 20mM sodium phosphate 
pH 7.0, 150mM NaCl, 2mM EDTA) and the protein eluted with elution buffer (elution buffer: 
100mM glycine pH 2.7). Eluted protein was neutralized with 20% 1M sodium carbonate pH 
9.0 and concentrated with Vivapin column cut off 10kDa (Vivascience AG, Hannover, 
Germany). Antibody was directly used for retargeting of AdFZ33βGal or stored at –20°C in 
elution buffer supplemented with 50% glycerin and 0.02% sodium azide until use.   
 
2.1.6 Differentiation of myoblasts into myotubes 
Fusion and differentiation of myoblasts into myotubes was induced by replacing the growth 
medium by DMEM containing 2% horse serum (Invitrogen Life Technologies, Karlsruhe, 
Germany). Cells were cultured for a minimum of 5 days until multinucleated myotubes had 
formed. 
 
2.2 Viral vectors 
2.2.1 Propagation and purification of adenoviral vectors  
The viral vector AdEGFP was a kind gift from Dr. Christoph Volpers and generated by 
insertion of a blunted AflIII/AflII fragment from pEGFP-N1 (Clontech, Heidelberg, Germany) 
into the PacI site of pGS66221 after removal of overhanging ends with T4 DNA polymerase. 
The plasmid pAdEGFP contains an EGFP open reading frame under control of the CMV 
promoter and an SV40 polyA region at the 3‘ end in a left-to-right orientation (identical to the 
Ad19aEGFP) in the E1 region of the Ad5 genome between the left ITR and the E2 
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transcription unit. Rescue and propagation of Ad vectors: The EGFP reporter vector AdEGFP 
which was used as a control vector (unmodified Ad5 capsid) and was rescued by transfection 
of 10µg of SwaI-cut pAdGFP DNA into N52.E6 cells221 by the calcium phosphate method. 
Plaques were picked after eight days from the agarose overlay of the culture plate, the vector 
was amplified by serial propagation on N52.E6 cells and purified by CsCl equilibrium density 
gradient centrifugation as previously described222.  
The first generation vector Ad19aEGFP was provided by Dr. Ruzsics. Ad19aEGFP contains 
the E1-deleted adenovirus 19a backbone with an EGFP open reading frame under control of 
the CMV promoter and an SV40 polyA region at the 3‘ end in a left-to-right orientation.  
 
2.2.2 Construction of AdFZ33βGal 
 Dr. Volker Biermann constructed the vector AdFZ33βGal by insertion of the nucleotide 
sequence encoding the Z33-peptide into the fiber HI loop region of pVB6. Three pairs of 5'-
phosphorylated oligonucleotides: 
5'-TAAGTTTAACATGCAGCAGCAGCGCCGCTTTTAC-3' and 5'-CGGCGCTGCTGCT-
GCATGTTAAACTTAAT-3', 5'-GAGGCCCTGCACGACCCCAACCTGAACGAGGAGC-
AG-3' and 5'-CTCGTTCAGGTTGGGGTCGTGCAGGGCCTCGTAAAA-3', as well as 5'-
CGCAACGCCAAGATTAAGAGCATTCGCGACGACAT-3' and 5'-
CGATGTCGTCGCGAATGCTCTTAATCTTGGCGTTGCGCTGCTC-3', 
were annealed and ligated to the PacI/ClaI-cleaved expression plasmid pVB6192. The 
infectious adenovirus plasmid pVB6 contains the genome of a first-generation Ad vector with 
a CMV promoter/lacZ expression cassette replacing the E1 region and unique PacI and ClaI 
restriction sites at Ad5 nucleotide position 32,670 in the HI loop region of the fiber gene. The 
correct sequence and position of the insert was confirmed by cycle sequencing. 
Rescue and propagation of AdFβGal, and AdFZ33βGal. 10 µg of pVB6 and pVB44 DNA, 
respectively, were cleaved with SwaI, followed by phenol extraction and ethanol precipitation. 
The DNA was transfected into N52.E6 cells by the calcium phosphate method and the cells 
harvested after 14 days when they showed cytopathic effect (CPE). After three cycles of 
freeze/thawing to release vector particles N52.E6 cells were infected with half of the cell 
lysate, and the cell monolayer was overlaid with 0.5% agarose mix. After plaque purification, 
the Ad vectors were propagated in N52.E6 cells as previously described222. Following CsCl 
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equilibrium density gradient centrifugation, the infectious titer of AdFβGal and AdFZ33βGal, 
respectively, was determined by standard β-galactosidase assay on 293 cells223. 
 
2.2.3 Titration of adenoviral vectors 
The virus titer was expressed either in viral genomes per ml (vg/ml) as determined with real 
time PCR, or in gene transfer units [GTU] as previously described223,224. Quantification of 
adenoviral genomes was performed by means of quantitative PCR. Genomic titers of CsCl 
gradient-purified virus preparations were determined using real-time fluorescence detection 
ABI Prism 7000 Sequence Detector (Applied Biosystems, Foster City, USA) and SybrGreen 
as a double-stranded DNA-specific fluorescent dye (Applied Biosystems, Foster City, USA). 
Serial dilutions of plasmid pEGFP-N1 (Clontech, Palo Alto,USA) were used to obtain a 
standard calibration curve and fluorescence threshold values (Ct) plotted against plasmid copy 
numbers. The primers EGFPf214 (5’GCAGTGCTTCAGCCGCTAC3’), and EGFPr309 
(5’AAGAAGATGGTGCGCTCCTG 3’) were designed with the software Primer Express 
(Applied Biosystems, Foster City, USA) and their working concentration optimized according 
to the manufacturer’s guidelines.  
Capsid-free viral DNA was used as template and prepared as previously reported224. The PCR 
amplification was preceded by Uracil-N-glycosidase (Applied Biosystems, Foster City, USA) 
treatment for 2 min at 50°C and followed by a denaturation step of 10 min at 94°C and 40 
cycles of 15 s at 95 °C, 30 s at 60°C, and 30 s at 72°C. 
 
2.3 Retargeting of AdFZ33βGal 
2.3.1 Monoclonal and polyclonal antibodies  
the following antibodies were used for adenovirus retargeting: Mouse IgG2a type monoclonal 
anti-human EGFR antibody (mAb) LA22 (Upstate Biotechnology, Lake Placid, USA), anti-
human CD3 mAb HIT3a (Pharmingen BD, Hamburg, Germany), anti-human p53 mAb DO-1 
(Santa Cruz Biotechnology, Santa Cruz, USA), monoclonal antibody 2A6 specific for 
adenovirus trimeric fiber protein (NeoMarkers, Westinghouse, USA), and polyclonal anti Ad5 
hexon antibody (Biotrend, Köln, Germany). Antibody mAb-15 against integrin beta 3 was 
kindly provided by Dr. Gawaz (Medizinische Klinik, Klinikum rechts der Isar, und Deutsches 
Herzzentrum, Technische Universität München, Germany). The mAbs 3C12 and 6A11 
against mouse α7-integrin were obtained from Prof. Dr. Helga von der Mark (University of 
 
 
38
Erlangen, Germany)225,226. The anti-human NCAM mAb 5.1H11227 was a kind gift by Dr. 
Shoubridge (Montreal Neurological Institute, McGill University, Canada). Anti-NCAM and 
anti-α7 integrin antibodies were affinity-purified from hybridoma cell culture supernatant with 
protein G-agarose (Roche Diagnostics, Mannheim, Germany). The purity of antibody 
preparations was higher than 90%, as assessed by polyacrylamide gel electrophoresis 
followed by silver staining250. Protein concentrations of purified antibody preparations were 
determined with a colorimetric bicinchoninic acid (BCA)-based protein detection and 
quantitation assay (Pierce, Rockford, USA). A polyclonal antibody against the Ad5 fiber knob 
was raised in rabbits by immunization with recombinant purified knob protein (Charles River 
Deutschland, Kißlegg, Germany). Anti-MHC class I antibody W6/32 was kindly provided by 
Dr. Ruzsics (Max-von-Pettenkofer Institut, München, Germany). 
 
2.3.2 Complex formation between AdFZ33βGal and antibodies 
In order to form antibody-virus complexes, AdFZ33βGal vector (MOI=10) was preincubated 
with retargeting mAbs at different concentrations in serum-reduced Opti-MEM medium 
(Invitrogen Life Technologies, Karlsruhe, Germany) for one hour at room temperature. The 
cell culture media was replaced with Opti-MEM (Invitrogen Life Technologies, Karlsruhe, 
Germany) supplemented with 2% fetal bovine serum containing ultra low IgG amounts 
(Invitrogen Life Technologies, Karlsruhe, Germany), and 4 µl of the preincubated 
AdFZ33βGal vector antibody complexes added to the cells for 1h on ice. Cells were washed 
twice with Opti-MEM and further incubated with 10% FBS-containing growth medium for 48 
hours at 37°C until the transgene expression was quantified. 
   
2.4 Adenovirus transduction and competition assays 
2.4.1 Adenoviral transduction and competition assays for AdFZ33βGal 
One day prior to transduction fetal human myoblasts (FHM) were seeded in 96-well (1x104 
cells per well) flat-bottom tissue culture plates (Corning Glass Works, Corning, USA).  
For competition experiments the Ad vector was preincubated with mAb as described and 
transduction done in the presence of 20µg/ml recombinant Knob protein, 20µg/ml KnobZ33 
protein, or 10µg/ml staphylococcal protein A fragment, respectively. Cells were washed twice 
with Opti-MEM and further incubated with 10% FBS-containing growth medium for 48 hours 
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at 37°C until the transgene expression was quantified. Transduction efficiencies were 
evaluated by luminometric quantification of β-galactosidase activity or X-Gal staining.  
 
2.4.2 Virus transduction assay 
One day prior transduction fetal human myoblasts (FHM) were seeded in 48-well (1x104 cells 
per well) flat-bottom tissue culture plates (Corning Glass Works, Corning, USA) and 
transduced over night (16h) in Opti-MEM medium (Invitrogen Life Technologies, Karlsruhe, 
Germany) supplemented with 2% FBS with 1250, 2500, and 12500 viral genomes per cell 
(vg/cell). Cells were washed twice with Opti-MEM and further incubated with 10% FBS-
containing growth medium for 48 hours at 37°C until the transgene expression was quantified. 
 
2.4.3 Virus transduction competition assay 
One day prior transduction fetal human myoblasts (FHM) were seeded in 48-well (1x104 cells 
per well) flat-bottom tissue culture plates (Corning Glass Works, Corning, USA).  
For competition experiments Ad5EGFP and Ad19aEGFP vectors were preincubated with 
10µg/ml Ad19a fiber protein, purified knob proteins (Ad19a knob: 10µg/ml and 100µg/ml; 
Ad5 knob: 10µg/ml), 2mM GRGDS peptide (Sigma), 10 µg/ml heparin (Sigma), 50µg/ml 
wheat germ agglutinin (Sigma), α(2-3) neuraminidase (New England Biolabs, Berverly, 
USA) alone, or combinations thereof, respectively, in Opti-MEM supplemented with 2%FBS. 
Incubation with competing substances was done for 1h on ice prior to vector addition. Cells 
were transduced with Ad5EGFP and Ad19aEGFP (MOI=20) for 1h on ice. Then the cells 
were washed twice with Opti-MEM and further incubated with 10% FBS-containing growth 
medium for 48 hours at 37°C until the transgene expression was quantified. 
Virus internalization-competition assay: Cells were incubated with inhibiting substances for 
1h on ice as described above, and transduced with virus (MOI=20) for 1h at 37°C. Then the 
cells were washed twice with Opti-MEM and further incubated with 10% FBS-containing 
growth medium for 48 hours at 37°C until the transgene expression was quantified. 
 
 
2.4.4 Quantification of transgene expression 
Transgene expression in cells transduced with EGFP-expressing vectors (Ad5EGFP, 
Ad19aEGFP) was evaluated using a fluorescence multi-well plate reader (Perseptive 
Biosystems, Framingham, USA). Fluorescence was stimulated by excitation of EGFP at 
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488nm and emitted fluorescence measured at 508nm. Transgene expression of cells 
transduced with vectors expressing β-galactosidase (Ad5βGal, AdFZ33βGal) was evaluated 
by luminometric quantitation of β-galactosidase activity. For luminometric quantitation of β-
galactosidase activity equal amounts of protein were incubated with Galacto-Star reagent (PE 
Biosystems, Weiterstadt, Germany) according to the manufacturer's instructions and light 
emission measured in a Berthold plate luminometer (Berthold, Bad Wildbad, Germany). Total 
amount of cell protein was determined with micro BCA protein assay (Pierce, Rockford, 
USA).  
  
2.4.5 Flow cytometry (FACS) 
For CD11c surface staining of monocyte-derived dendritic cells 5 x 105 cells were labeled 
with PE-conjugated primary anti-CD11c antibody (50µg/ml) (DakoCytomation, Glostrup, 
Denmark) for 30min at RT in 500µl FACS buffer (PBS containing 1%FBS). Cells were 
washed 3 times with PBS and fixed with PBS containing 1% paraformaldehyde (PFA) for 30 
min at RT. Next, cells were washed once with PBS and resuspended in 500µl FACS buffer 
supplemented with 0,01% NaN3 for analysis on a FACScan (Becton Dickinson Bioscience, 
Heidelberg, Germany). A total of 10000 cells per experiment were analyzed. 
 
2.4.6 Confocal laser immunofluorescence and immunofluorescent staining of human muscle 
cells 
The protocol for detection of surface NCAM expression on fetal human myoblast-derived 
myotubes by immunofluorescence was adapted from Walsh et al.228. Human myoblasts and 
myotubes were grown on laminin-1 coated glass cover slips and incubated with 5.1H11 
hybridoma supernatant diluted 1:100 in PBS for 45min at RT. Cells were washed thoroughly 
with PBS and incubated with Cy3-conjugated sheep-anti mouse secondary antibody 
(DakoCytomation, Glostrup, Denmark) diluted 1:200 in PBS supplemented with 10% FBS for 
45 min at RT. Cells were washed twice with PBS and fixed with 2% PFA/PBS for 5 min at 
RT. For confocal laser microscopy of virus-infected cells CHOαvβ3 cells were cultured on 
cover slips (Menzel Gläser, Braunschweig, Germany). Internalization of Ad5 vector into 
CHOαvβ3 cells was analysed at 2 time points (15min and 45 min). Ad5βGal vector 
(MOI=1000) was added to CHOαvβ3 cells for 1h on ice. Internalization was induced by 
incubating the cells at 37°C for the indicated times followed by immediate fixation with 2% 
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PFA/PBS for 20 min on ice. For staining, coverslips were blocked for 1h at RT with 
10%FBS/PBS and co-stained with anti-hexon antiserum and anti-β3 integrin mAb Ab-15 
(both 50µg/ml) diluted in PBS containing 0.2% Triton X-100 (Sigma). TRITC-conjugated rat 
anti-goat and fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse secondary 
antibodies (50µg/ml) were used as secondary antibodies (DakoCytomation, Glostrup, 
Denmark). Immunofluorescence analysis was performed on a Leica confocal laser microscope 
with TCS software program. 
 
2.4.7 Visualization of transgene expression (X-Gal) and fluorescence microscopy 
β-galactosidase expression in transduced cells was visualized by means of X-Gal staining 
according to a standard protocol229. Pictures of fluorescent cells were recorded with AxioCam 
HRC (Zeiss, Jena, Germany) on a Leica DMRBE epifluorescence microscope and analyzed 
with AxioVision 3.1 software (Zeiss, Jena, Germany). 
 
  
2.5 Expression and purification of viral proteins 
2.5.1 Cloning, expression and purification of recombinant fiber proteins in E.coli 
The bacterial expression plasmid pTrcK19a was generated by PCR-amplification of the fiber 
gene region encoding knob domain amino acids (aa) 187 to 365 by use of forward and reverse 
primers containing non-hybridizing EcoRI and BamHI restriction site sequences, respectively. 
The PCR product was purified, cut with EcoRI and BamHI, and ligated to EcoRI/BamHI-
cleaved pTrcHisB (Invitrogen Life Technologies, Karlsruhe, Germany). Primer sequences for 
Ad19a knob PCR are: Knob19aF (5’ATATGGATCCAGTAAGAGCAAGAGAAGG3’), and 
Fiber19aR (5’TTATGAATTCTGGTCTTTCATTCTTGGGC3’). The bacterial expression 
plasmid pTrcK5 was generated by PCR-amplification of the fiber gene region encoding knob 
domain amino acids (aa) 387 to 581 by use of forward and reverse primers containing non-
hybridizing EcoRI and BclI restriction site sequences, respectively. The PCR product was 
purified, cut with EcoRI and PstI, and ligated to EcoRI/BclI-cleaved pTrcHisB (Invitrogen 
Life Technologies, Karlsruhe, Germany). Primer sequences for Ad5 knob PCR are: Knob5F 
(5’CAATGATCATGGCCTAGAATTTGAT3’), and Knob5R (5’ATAGAATTCCTATTCTT 
GGGCAATGTATG3’). The Ad19a fiber transfer plasmid pTrcFib19a was generated by 
cloning the EcoRI/BamHI restricted PCR-fragment encoding Ad19a fiber into EcoRI and 
BamHI sites of the bacterial expression vector pTrcHisB  (Invitrogen Life Technologies, 
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Karlsruhe, Germany). Amplification by PCR of the Ad19a fiber gene was done using Ad19a 
fiber-specific primers containing non-hybridizing EcoRI and BamHI restriction sites. Primer 
used for Ad19a fiber PCR are: Fiber19aF (5’ATATGGATCCAATGTCAAAGAG 
GCTCCG3’), and Fiber19aR (see above). For recombinant expression of knob proteins E.coli 
strain BL21 (Stratagene, La Jolla, CA, USA) was transformed with plasmids pTrcK5 and 
pTrcK19a, respectively, and protein expression induced with 0.1mM isopropyl-β-D-
thiogalactopyranoside (Sigma, Deisenhofen, Germany). Knob proteins were affinity-purified 
with Ni-NTA Agarose (Qiagen, Hilden, Germany) according to standard protocols.  
 
2.5.2 Cloning, expression and purification of fiber proteins in SF9 cells 
The baculovirus transfer plasmid pFB-Knob was generated by PCR-amplification of the fiber 
gene region encoding knob domain amino acids (aa) 387 to 581 by use of forward and reverse 
primers containing non-hybridizing EcoRI and PstI restriction site sequences, respectively, 
and adding a 6xHis-tag encoding sequence to the 5'-end. The PCR product was purified, cut 
with EcoRI and PstI, and ligated to EcoRI/PstI-cleaved pFastBac1 (Invitrogen Life 
Technologies, Karlsruhe, Germany). The plasmid pFB-KnobZ33 was constructed in the same 
way, using pVB45 as a template for PCR. The transfer plasmid pFB-CAR was obtained by 
PCR-amplification of the extracellular CAR region encoding aa 1-236 with primers 
containing BamHI and XbaI restriction site sequences. After cloning into BamHI/XbaI-cut 
pFastBac1, oligonucleotides encoding a Flag-tag and a subsequent stop codon were annealed 
and inserted into the XbaI site. 
The transfer plasmids pFB-Knob, pFB-KnobZ33 and pFB-CAR were used to rescue 
recombinant baculoviruses according to the Bac-to-Bac-protocol (Invitrogen Life 
Technologies, Karlsruhe, Germany). Cell culture medium supernatants from transfected insect 
cells were harvested and recombinant baculoviruses propagated by two rounds of 
amplification. For expression of Knob protein and KnobZ33 protein, respectively, 
baculovirus-infected Sf9 cells were harvested 72 hours p.i., washed with phosphate-buffered 
saline, and resuspended in 5 ml dounce buffer (10 mM sodium phosphate buffer pH 8.0, 10 
mM NaCl, 1.5 mM MgCl2) per 1.8x108 cells. After incubation on ice for 10 min, cells were 
lysed by 50 strokes in a tight-pistill glass/teflon homogenizer. The lysate was cleared by 
centrifugation at 5000 x g for 15 min and adjusted to equilibration buffer (50 mM sodium 
phosphate buffer, 300 mM NaCl, 10 mM Imidazole). His-tagged recombinant proteins were 
purified from the lysate in a batch procedure by incubation with Ni-NTA agarose beads 
 
 
43
(Qiagen, Hilden, Germany) for 2 hours at 8°C. After washing the beads three times for 10min 
with equilibration medium the protein was eluted in one bead volume of elution buffer 
(equilibration buffer with 250 mM Imidazole) and dialysed against phosphate-buffered saline. 
For expression of soluble CAR (sCAR) protein, Hi-Five cells in serum-free media were 
infected with the recombinant baculovirus, and the Flag-tagged sCAR protein was purified 
from the cell culture supernatant by affinity chromatography on anti-Flag agarose (Sigma, 
Deisenhofen, Germany). 
For construction of the baculovirus transfer plasmid pFB-Fiber19a, the 1.2-kb fragment 
containing the complete fiber open reading frame of Ad19a was cut out of plasmid 
pTrcFib19a with BamHI and EcoRI and inserted into pFastBacHTa (Invitrogen Life 
Technologies, Karlsruhe, Germany) (BamHI/EcoRI). The transfer plasmid pFB-Fiber19a was 
used to rescue a recombinant baculovirus according to the Bac-to-Bac protocol (Invitrogen 
Life Technologies, Karlsruhe, Germany). Cell culture medium supernatant from transfected 
Sf9 insect cells was harvested and recombinant baculovirus propagated with three rounds of 
amplification. Expression of full-length Ad19a fiber protein carrying a 6xHis tag at the N-
terminus in insect cells and purification by Ni-NTA affinity chromatography was performed 
according to the manufacture’s recommendations.  
 
2.5.3 Cloning, expression and purification of fiber proteins using recombinant vaccinia virus 
For construction of the vaccinia virus shuttle plasmid pTkgFZ33, a fragment encoding 10.5 
fiber shaft repeats and the Z33 knob domain was amplified by PCR from plasmid pVB44 
using the primers 10.5NotIHis6 (5’ATAGAATTCTGCGGCCGCTTATTAATGATGA 
TGATGATGATGTTCTTGGGCAATGTATG 3’), and 10.5HindIII (5’ATATTAAAGCTT 
GCCACCATGGACCTAAACACTTTGACC3’). Primer 10.5NotIHis6 contains a non-
hybridizing NotI restriction site followed by a hexa-His encoding sequence. Purified PCR 
fragments were cut with NotI and HindIII and ligated to NotI/HindIII-digested vaccinia virus 
expression plasmid pTkg230, yielding pTkgFZ33.  
 
Generation of pTkgFZ34C vaccinia virus shuttle plasmid 
For construction of the vaccinia virus shuttle plasmid pTkgFZ34C, a nucleotide sequence 
encoding for Z34C-peptide was inserted into the PacI/ClaI digested pTkgFZ33. The 
nucleotide sequence encoding for Z34C was obtained by ligation of annealed pairs of 5'-
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phosphorylated oligonucleotides (A1, A2, B1, and B2) to the PacI/ClaI-digested expression 
plasmid pFZ33. A1( 5’TAAAAGCAAAAGCAAAAGCAAAAGCAAATT 
CAACATGCAGTGCCAGAGAAGATTCTACGAAGCTCTCCACGACCCTAACCTGAAC
GAAGAA3’); A2 ( 5’CAGAGAAACGCTAAAATCAAAAGCATCAGAGACGACTGCA 
AAAGCAAAAGCAAAAGCAAAAGCAAAAT3’); B1 (5’GAGAGCTTCGTAGAATCT 
TCTCTGGCACTGCATGTTGAATTTGCTTTTGCTTTTGCTTTTGCTTTTAAT3’); B2 
(5’CGATTTTGCTTTTGCTTTTGCTTTTGCTTTTGCAGTCGTCTCTGATGCTTTTGATT
TTGACGTTTCTCTGTTCTTCGTTCAGGTTAGGGTCGTG3’). 
  
Generation of recombinant vaccinia virus 
Vaccinia virus transfer plasmids were transfected in CV-1 cells using the calcium phosphate 
method and recombined with wild-type vaccinia virus (WR strain) in vivo. Recombinant 
vaccinia viruses were selected with mycophenolic acid as previously described230. Briefly, 
1x106 confluent CV-1 cells were infected with MOI=5 wild type vaccinia virus and 
subsequently transfected with vaccinia virus shuttle plasmids. Insertion of the transgene 
occurs via homologous recombination within the thymidine kinase (TK) gene. The resulting 
recombinant vaccinia viruses are deficient for thymidine kinase (TK-) and carry E. coli 
xanthine-guanine phosphoribosyltransferase (XGPR) as second selection marker. Selection of 
recombinant vaccinia viruses was done with mycophenolic acid (MPA), which inhibits 
inosinemonophosphate dehydrogenase (IMPDH), an enzyme that is essential for 
guaninemonophosphate (GMP) biosynthesis. Rescue of recombinant vaccinia viruses carrying 
the XGPR selection marker was done by addition of xanthine to the MPA-containing 
selection medium (DMEM supplemented with 2.5% FBS, containing 25µg/ml MPA; 
250µg/ml xanthine, and 15µg/ml hypoxanthine). E.coli xanthine-guanine 
phosphoribosyltransferase is able to convert Xanthine into xanthinemonophosphate (XMP), 
which can be further processed to gunaninemonophosphate (GMP). Recombinant viruses 
were subjected to 3 rounds of plaque-purification. Selected recombinant vaccinia viruses were 
amplified in CV-1 cells. Recombinant viral stocks were generated by infection of 1x108 CV-1 
cells with recombinant vaccinia virus (MOI=1). Cells showing complete CPE were harvested, 
resuspended in 5ml PBS, and subjected to 3 rounds of freeze/thawing. Virus stocks were 
stored at –80°C until use. Contamination of recombinant vaccinia virus stocks was excluded 
by means of a sensitive PCR-based detection method. Briefly, genomic DNA from virus-
infected CV-1 cells was isolated using the genomic DNA preparation blood kit (Qiagen, 
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Hilden, Germany). Contaminating wild type vaccinia virus was detected by amplification of a 
619bp long fragment from the thymidine kinase gene spanning the integration site. The 
primers used for amplification are the following: TKFor (5’ ATCCTCGTCGCAATATCGC 
3’) and TkRev (5’ ATTATGAGTCGATGTAAC 3’). Amplification protocol was 94°C, 3min; 
27x [94°C, 30s; 55°C, 1min; 72°C, 90s]; 72°C, 7min; hold 4°C.  
 
2.5.4 Detection of trimeric fiber proteins in vaccinia virus-infected cells by means of semi-
native polyacrylamid gel electrophoresis 
CV-1 cells (3x107) were infected with recombinant vaccinia virus (MOI=10) expressing FZ33 
and FZ34Z proteins, respectively. Cells were harvested after 16h and lysates from vaccinia-
infected CV-1 cells prepared as previously described231. Proteins were separated on a 7.5% 
SDS-PAA gel. Western blot analysis: Recombinant proteins were incubated in sample buffer, 
boiled for 5 min, and subjected to 10% sodium dodecylsulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE)232. For semi-native electrophoresis, protein lysates were not 
boiled and sample buffer without β-mercaptoethanol used. Proteins were separated on a 7.5% 
SDS-PAGE gel and subsequently blotted onto a nitrocellulose membrane. The blots were 
developed using the trimeric fiber-specific monoclonal antibody 2A6 (1:1,000 in TBST 5% 
skimmed milk) and a peroxidase-coupled goat anti-mouse secondary antibody diluted 1:5000 
in TBST 5% skimmed milk (Jackson ImmunoResearch, Dianova, Hamburg). 
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3. Results 
 
3.1 Molecular mechanism of adenovirus serotype 5 for binding and entry into primary 
human muscle cells. 
 
In order to determine the molecular mechanism which is used by Ad5 to infect muscle cells, 
experiments aimed to identify receptors involved in virus binding and uptake to myoblasts 
and differentiated myotubes were undertaken. Virus binding and internalization can be 
experimentally dissociated from each other at low temperature (0-4°C), where only virus 
attachment occurs, whereas endocytosis of viral particles takes place at higher 
temperatures9,40. 
 
3.1.1 Attachment of Ad5 to human muscle cells involves more than one receptor 
In order to identify receptors involved in virus attachment to primary human muscle cells 
(FHMs), cells were treated with substances known to interfere with binding of Ad5 to cellular 
virus attachment and internalization receptors. Cells were treated either with recombinant Ad5 
knob protein, GRGDS peptide, and heparin alone, or combinations thereof. To test the 
bioactivity of recombinant Ad5 knob protein, the CAR overexpressing rat muscle cell line 
(L6CAR) was transduced with Ad5 (MOI 50) using competing amounts of WTKnob protein 
and non-CAR binding mutated knob protein (MUTKnob) during the infection174. Infection of 
L6CAR cells by adenovirus was efficiently (>90%) inhibited using less than 1µg/ml 
recombinant Ad5 knob protein, whereas no inhibition occurred with MUTKnob even at higher 
concentrations. Therefore it was concluded that, Ad5 knob protein binds to CAR and infection 
of L6CAR cells depended almost exclusively on interaction of Ad5 with CAR (Fig.5). 
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Fig.5 Introduction of two point mutations into Ad5 fiber knob (K417I+K420I) prevents binding of the Ad5 
fiber knob to its cellular receptor CAR. L6CAR cells were transduced for 2h at 37°C with β-galactosidase 
expressing adenovirus (Ad5βGal) in the presence of increasing amounts of wt-Ad5 knob protein (Wtfiber) or 
mutant Ad5 knob protein (Mutfiber). Addition of 1µg/ml wt knob protein to the infection medium inhibited the 
transduction of FHMs by (>90%), whereas addition of mutated knob protein had no influence on transfection. β-
galactosidase activity in relative light units [RLU] was quantified after 48h. Data shown represent the means ± 
SD of three independent experiments. 
 
Interaction of Ad5 with its secondary receptors αvβ3 and αvβ5 can be inhibited with soluble 
GRGDS peptide9, whereas heparin can be used to compete with Ad5 for binding to heparan 
sulfate glucoseaminoglycans (HSGs)23,24. First the optimal working concentrations were 
determined for each substance. Maximal inhibitory activity for attachment of Ad5 (MOI=10) 
to FHM occurred at 10µg/ml heparin, 2mM GRGDS peptide, and 10µg/ml knob protein, 
respectively (data not shown). Incubation of FHM with competing substances partially 
decreased binding of Ad5 to FHM. Additive effects were observed when heparin was 
combined with knob protein and virus attachment reduced by 80 ± 2% (Fig.6A). In order to 
investigate Ad5 internalization, cells were preincubated for 1h at 4°C with competing 
substances and vector added for 1h at 37°C. Preincubation with knob protein led to 40±1,6 % 
reduction of transgene expression, pre-incubation with heparin decreased transgene 
expression by 39±4,3 %, competition with GRGDS peptide decreased transgene expression by 
25±2,4 %, whereas additive effects were observed when GRGDS was combined with knob 
protein and heparin, respectively. GRGDS combined with Ad5 knob protein decreased 
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transgene expression by 66±5,2 %, and GRGDS combined with Heparin reduced expression 
by 60±8,3 %, respectively (Fig.6B).  
Additive inhibitory effects of GRGDS peptide and Ad5 knob, and GRGDS and heparin have 
only been observed at 37°C, but not at 4°C, a temperature non-permissive for virus 
internalization. These results are in agreement with the proposed two-step model for Ad5 
infection7,9, and support recent findings, stating a role for heparansulfate glucosaminoglycans 
(HSGs) in Ad5 transduction in vitro23,24. Myotubes behaved similarly as myoblasts. Binding 
of Ad5 to myotubes was sensitive to knob protein and heparin, but not to RGD peptide, 
whereas internalization was sensitive to knob protein and soluble GRGDS peptide (data not 
shown). 
 
 
Fig.6 Attachment and internalization of Ad5 to human primary myoblasts. Myoblasts (MB) were pretreated 
for 1h on ice with 2mM GRGDS peptide, 10mM heparin, 10µg/ml recombinant Ad5 knob or combinations 
thereof, and virus (MOI=10) added for 1h on ice (A). Cells were preincubated with inhibiting substances as 
indicated for 1h at 4°C, and then virus (MOI=10) added for 1h at 37°C (B). The data represent the mean 
percentage of transgene expression per 1µg total protein ± SD from three independent experiments normalized to 
FHMs transduced with AdFβGal (control=100%). 
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3.2 Antibody-mediated targeting of an adenoviral vector, modified to contain a synthetic 
IgG-binding domain in the capsid 
 
3.2.1 Incorporation of the antibody-binding Z33-domain into the Ad5 HI-loop 
Acute adenovirus-mediated vector cytotoxicity is a dose-dependent process leading to loss of 
transgene expression in transduced cells233. Transduction of non-target cells, especially 
antigen-presenting cells, is known to mediate anti-virus and anti-transgene immune responses. 
Consequently, the major goals for adenovirus vector development are to simultaneously 
decrease the vector dose needed for efficient transduction, and second, to increase the 
specificity of virus infection. Therefore, we decided to design a versatile retargeting system, 
which would allow us to screen new adenovirus entry receptors, simply by exchanging the 
monoclonal antibodies bound to Ad vector particles.  
A stable variant of the immunoglobulin (Ig)-binding B-domain of the staphylococcal protein 
A234, the so-called Z-domain, is a triple alpha-helical 59-amino-acid peptide that binds to the 
Fc portion of IgG with high affinity235,236. The entire Z-domain or derivatives thereof have 
been incorporated into capsid proteins of baculovirus237,238, sindbis virus239,240, and recently 
into the capsid of adeno-associated virus (AAV2)241.  
In this work a fiber-modified Ad vector was generated (AdFZ33βGal), displaying a short 
modified version of the Z-domain (Z33) on its capsid242,243. The HI-loop was chosen as 
insertion site because it protrudes from the knob structure without contacting other knob 
residues (Fig.7).  
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Fig.7 Insertion of the functional Z33 ligand into the Ad5 HI loop. The HI loop (black) does not overlap with 
CAR binding AB loop (yellow) and was chosen as insertion site for the Z33 ligand. In order to insert ligands a 
cloning site containing PacI, SpeI and ClaI restriction enzyme recognition sites was introduced into the Ad5 HI 
loop at its most distant site (Asp 544) (A). Genomic organization of the Ad5-based, fiber-modified vector 
AdFZ33βGal, containing the Z33-peptide inserted into PacI/ClaI restriction sites in the HI-loop, and the control 
vector AdFβGal containing only the PacI/ClaI restriction site sequence in the HI-loop. Numbers refer to 
nucleotide positions in the Ad5 genome (B). 
 
 
 
3.2.2 Functionality of mutant fiber genes expressed in CV-1 cells 
The recombinant fiber molecule containing the Z33-insertion had to retain basic features for 
functionality: trimerization of the fiber protein, which is essential for proper virus assembly, 
and Fc-binding activity of the Z33-domain, which would allow for the complexation with 
targeting antibodies.  
These essential activities were first assessed at the molecular level of recombinant proteins 
and baculoviral and vaccinia expression vectors constructed. Recombinant vaccinia viruses 
expressing a truncated (10.5 fiber shaft repeats) Ad5 fiber with Z33 (FZ33), and Z34C-
modified (FZ34C) HI-loops, respectively, were constructed. FZ34C is based on an improved 
minimized domain of the immunoglobulin (Ig)-binding B-domain of the staphylococcal 
protein A, and contains two N-and C-terminal cystein residues forming a disulfide bond, 
conferring supplemental structural stability and higher affinity to IgG244.  
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Selection of recombinant vaccinia virus 
The selection of recombinant vaccinia virus is based on the integration of the transgene 
together with a selection marker gene E. coli xanthine-guanine phosphoribosyltransferase 
(XGPRT) into the thymidine kinase gene of vaccinia virus.  
A PCR-based protocol was set up to screen for contaminating wild type vaccinia virus in 
recombinant stocks. A primer pair flanking the integration site within the thymidine kinase 
gene (TkFor x TkRev) was chosen to discriminate between recombined and WT Vaccinia virus. 
A small fragment of 619 bp length is amplified from WT Vaccinia virus DNA, whereas much 
larger fragments > 4kb are amplified from recombinant vaccinia virus DNA (Fig.8A). After 
selection of recombinant vaccinia viruses and infection of CV-1 cells with 10 infectious 
particles per cell230, expression of proteins was analysed by Western blot under semi-native 
and denaturing conditions (Fig. 8B). Two bands migrating at approximately 130-140kDa were 
detected under semi-native conditions with the trimer-specific antibody 2A6245, corresponding 
to the trimeric FZ33 and FZ34C fiber mutants, respectively. As expected, under denaturing 
conditions, the bands disappeared. This result demonstrated that insertion of Z33 and Z34C 
ligands into the HI loop did not compromise the trimerization of fiber protein, and thus would 
not interfere with rescue of recombinant adenoviruses.  
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Fig.8 Generation of recombinant vaccinia virus expressing Z33- and Z34C-modified fiber proteins. 
Schematic representation of pTkg vector with multiple cloning site (MCS) flanked by thymidine kinase 
homology regions I and II. The plasmid pTkg contains the selection marker gene E.coli xanthine-
guaninephosphoribosyltransferase (XGPT). PCR-based detection of contaminating wild type vaccinia virus 
(VacciniaWT) results in the generation of a small 619bp long PCR product, whereas long PCR-products are 
detected in wild type-free stocks of recombinant vaccinia viruses. PCR products were separated on a 0.8% 
agarose gel and ethidiumbromide used to visualize the bands under UV light. Large PCR products corresponding 
to wild-type-free recombinant GFP-expressing vaccinia virus (GFP clone 5), and wild-type-free recombinant 
FZ34C vaccinia virus stock (FZ34C clone 5), respectively, were amplified (A). Trimerization of fiber proteins 
FZ33 and FZ34C. Western blot of protein lysates (20µg/lane) from CV-1 cells infected with vaccinia virus 
expressing fiber mutants under semi-native (FZ33nat and FZ34Cnat) and denaturating conditions (FZ3395°C, 
and FZ34C95°C). Trimeric fiber proteins were detected using the Ad5 trimeric fiber-specific monoclonal 
antibody 2A6. The trimeric FZ33 and FZ34C bands disappeared after heat-denaturation of the lysate (95°C) 
(FZ3395°C and FZ34C95°C). Lysate from CV1 cells infected with GFP-expressing vaccinia virus was used as a 
negative control (CV-1 nat) and analysed under semi-native conditions (B).  
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 3.2.3 The Fc-binding Z33-domain retains its antibody-binding activity within the Ad5 fiber 
HI-loop 
The Fc-binding activity of knobZ33 was quantitatively assessed by surface plasmon 
resonance measurements. The data was kindly provided by Dr. Helmut Kewes (ZMMK, 
University of Cologne, Germany). The mouse monoclonal antibody (MAb) against human 
epidermal growth factor receptor (EGFR; MAb LA22) was immobilized on the surface of a 
BIAcore CM5 sensor chip and recombinant Knob and KnobZ33 protein were tested as 
analytes for binding, respectively. Binding constants calculated from primary data using a 
simple 1:1 model for interaction led to an average dissociation constant (KD) of 2.4 nM (Table 
2), which was consistent with the KD calculated from the equilibrium data using a Scatchard 
plot (KD = 5.7 nM). Expectedly, the wild-type knob protein did not bind to anti-EGFR MAb 
even at higher concentrations (25 and 307 nM). To further investigate whether the interaction 
with CAR, another function of the fiber knob domain, was affected by incorporation of the 
Z33-domain, we coupled Knob and KnobZ33 protein, respectively, on the surface of sensor 
chips and tested for binding of a purified recombinant soluble CAR (sCAR) protein. When 
various concentrations of sCAR (9 to 244 nM) were injected over a surface containing 1050 
RU of immobilized KnobZ33 and 1180 RU of Knob (not shown), respectively, both KnobZ33 
as well as wild-type Knob protein bound to sCAR protein with comparable affinity 
(KD(KnobZ33) = 494 nM; KD(Knob) = 409 nM). Thus, insertion of the Z33-peptide into the 
knob domain obviously had no influence on its binding to CAR. The affinity data are 
summarized in table 2. 
 
Table 2 
Ligand Analyte ka (1/Ms) kd(1/s) Kd (nM)) 
 
Anti-EGFR MAb LA22 
 
KnobZ33 
 
7.5 X 10e5 
 
1,8 X 10e-3 
 
2.4 
 
Anti-EGFR MAb LA22 
 
Knob 
 
No binding 
 
No binding 
 
No binding 
 
Anti-EGFR MAb LA22 
 
protein A 
 
1.9 X 10e6 
 
3.7 X 10e-3 
 
2.0 
 
KnobZ33 
 
sCAR 
 
1.1 X 10e5 
 
5.3 X 10e-2 
 
494 
 
Knob 
 
sCAR 
 
1.6 X10e5 
 
6.6 X10e-2 
 
409 
 
 
 
54
3.2.4 Rescue and functional analysis of AdFZ33βGal 
Based on a helper virus plasmid for generation of fiber knob HI-loop-modified high-capacity 
Ad vectors292 an infectious first-generation Ad vector plasmid (pAdFβGal) was constructed to 
contain a LacZ reporter gene under control of a CMV promoter in the deleted E1 region. In 
addition, pAdFβGal carries unique PacI and ClaI restriction sites at nucleotide position 
32,670 of the Ad5 genome for insertion of peptide ligands into the HI-loop of the knob 
domain. The infectious adenovirus plasmid pAdFZ33βGal was obtained after insertion of a 
Z33-domain encoding sequence via annealed oligonucleotides into the PacI/ClaI restriction 
sites of pAdFβGal. Both constructs were released from the plasmid backbone by SwaI 
digestion. Following transfection into N52.E6 producer cells246 the Ad vectors AdFβGal 
(control vector) and AdFZ33βGal (Z33-modified) were rescued (Fig.7B). The infectious titers 
of the CsCl gradient-purified Ad vectors were comparable (AdFβGal: 4x108 BFU/ml, 
AdFZ33βGal: 5x108 BFU/ml). To assess the functionality of AdFZ33βgal, we compared its 
ability to mediate gene transfer to FHM and compared it to AdFβGal and AdFK7. AdFK7 is a 
heparansulfate-retargeted adenovirus that was modified to carry 7 lysine residues in the HI 
loop184. AdFZ33βgal transduced primary human myoblasts 8-fold better than the unmodified 
vector AdFβGal. The poly-lysine retargeted vector AdFK7 transduced FHM 330-fold better 
than AdFZβGal (Fig.9).  
 
 
 
Fig.9 Transfection of FHM with retargeted adenovirus vectors. Comparison of gene transfer efficiency to 
FHM cells with Z33-modified adenovirus (AdFZ33βgal), poly-lysine K7-modified (AdFK7) vector, and 
unmodified control vector (AdFβGal). FHM cells were transduced with 10 BFU (blue forming units) per cell and 
β-galactosidase activity determined after 48h. β-Galactosidase activity was determined with Galactolight® assay 
and expressed as relative light units [RLU] per 1µg protein. Values represent means ± SD from 3 independent 
experiments. 
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Unlike other vectors (e.g. AAV), where incorporation of a targeting ligand reduce the biologic 
activity compared to the unmodified vector241, AdFZ33βGal showed enhanced gene delivery 
to FHM. 
 
3.2.5 Muscle-specific retargeting of AdFZ33βGal to NCAM and α7β1 integrin 
The development of muscle-specific gene transfer vectors is highly desirable for gene therapy. 
Only few muscle-specific receptors are known to be sufficiently expressed on dystrophic 
muscles and accessible to retargeted adenovirus. The capacity of AdFZ33βGal to transduce 
primary human myoblast when retargeted to muscle-specific candidate receptors like neuronal 
cell adhesion molecule (NCAM) and α7β1 integrin was explored. 
Since we believe, that the low expression of primary attachment and secondary internalization 
receptors on mature muscle fibers is responsible for the inefficient transduction of skeletal 
muscle, two abundant muscle specific cell surface antigens were selected for retargeting of 
AdFZ33βGal to skeletal muscle cells: integrin α7β1, a laminin receptor that is almost 
exclusively expressed on myoblasts and myofibers and overexpressed in dystrophic 
muscles247,285, and neural cell adhesion molecule (NCAM), which mediates intercellular 
contacts and is expressed in activated satellite cells and myogenic precursor cells during 
regeneration248,249,289. 
In an initial experiment, we tested several anti-NCAM antibodies for their ability retargeted 
AdFZ33βGal. Two hybridoma-derived and one polyclonal anti-NCAM antibody were used 
for vector retargeting (anti-human NCAM MAb clone UJ13A, anti-human NCAM MAb clone 
5.1H11 and polyclonal anti-human NCAM (C20)). When crude, antibody preparations were 
used to retarget AdFZ33βGal, the transduction efficiency was only moderately enhanced for 
all antibodies tested (Fig.10A).   
Since hybridoma supernatant was directly used, the antibody concentration might have been 
low, and furthermore, serum IgGs might have competed for antibody-binding sites on 
AdFZ33βGal. Therefore, we decided to adapt the hybridoma cells to serum free growth 
conditions and purified the antibody from supernatant by means of protein G affinity 
chromatography. Antibody produced by this method was >90% pure, as estimated on a silver 
stained gel after SDS-PAGE (Fig.10B). 
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Subsequently the pure NCAM-specific MAb 5.1H11 was used to redirect AdFZ33βGal to 
FHM. Whereas preincubation of the vector with MAb concentrations of 0.5 and 1 µg/ml had 
no significant effect on transduction efficiency, concentrations of 5 µg/ml  
 
 
 
 
Fig.10 Retargeting AdFZ33βGal to NCAM. Moderate enhancement of gene transfer efficiency to FHM was 
achieved upon retargeting AdFZ33βGal to NCAM using crude hybridoma supernatants UJ13A and 5.1H11, and 
commercially available polyclonal anti-NCAM antiserum C20 (A). The monoclonal antibodies anti-NCAM, 
clone 5.1H11, and anti-alpha 7 integrin MAb 3C12 were produced under serum free conditions and further 
affinity-purified with protein G. Aliquots of the purified antibodies were analysed by SDS-PAGE and the protein 
bands visualized by silver staining. Heavy and light chains of the purified antibodies were detected (B). 
Concentration-dependent increase of gene transfer efficiency using purified 5.1H11 anti-NCAM antibody. FHMs 
were transduced with 10 BFU/cell AdFZ33βGal retargeted with 5.1H11 and β-Gal activity determined after 48h. 
β-Gal activity was determined with Galactolight® assay as relative light units [RLU] per 1µg protein. Values 
were normalized to non-retargeted AdFZ33βGal (=100%), and represent means ± SD from 3 independent 
experiments (C). 
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 and higher improved reporter gene transfer in a dose-dependent manner (Fig.10C). Transgene 
expression levels were assessed with a luminometric β-galactosidase assay 48h post-
transduction. Transgene expression was enhanced 37-fold when the vector was pretreated 
with 40 µg/ml MAb 5.1H11 (Fig.10C). As expected, no targeting effect was obtained when 
AdFβGal was pretreated with Mabs (data not shown).  
Next, the ability of NCAM- and α7 integrin-retargeted AdFZ33βGal to increase the gene 
transfer to primary fetal human myoblasts (FHM) was compared (Fig.11). AdFZ33βGal was 
preincubated with increasing concentrations of MAb 3C12, 5.1H11, or control antibody 
directed against p53. A 24-fold increase of β-galactosidase expression was observed after 
preincubation of AdFZ33βGal with 40µg/ml 3C12, whereas NCAM-retargeted viruses proved 
superior, with 37-fold increased β-Gal activity at the same concentration (Fig.11A). In 
contrast, incubation of AdFZ33βGal with anti-p53 control antibody did only minimally (2.5-
fold increase at 40µg/ml MAb anti-p53) increase the gene transfer efficiency (Fig.11A). In 
agreement with the quantitative data X-Gal staining of FHMs transduced with NCAM- and 
integrin α7- retargeted vector demonstrated a dose-dependent increase of β-Gal positive cells 
with antibody-retargeted viruses (Fig. 11B). 
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Fig.11 Transduction of FHM with NCAM and α7 integrin retargeted AdFZ33βGal. Cells were transduced 
with AdFZ33βGal vector (MOI=10) preincubated with increasing concentrations of anti-integrin α7 MAb 3C12, 
anti-NCAM MAb 5.1H11, and anti-p53 antibody (control), respectively. β-Galactosidase activity was 
determined as relative light units (RLU) per 1µg protein and normalized to FHMs transduced with AdFZ33βGal 
alone (AdFZ33βGal=100%). Each value represents the means of three independent infections ± SD (A). X-Gal 
staining of transduced FHM cells. Cells were mock-transduced (mock), transduced with AdFZ33βGal alone 
(AdFZ33βGal), and transduced with retargeted AdFZ33βGal against integrin α7 (MAb 3C12) or NCAM (MAb 
5.1H11). For retargeting, AdFZ33βGal was preincubated with 20, and 40 µg/ml of the corresponding MAbs, 
respectively. β-Galactosidase expression was visualized with chromogenic X-Gal reagent after 48 hours (B). 
 
Myotubes differentiated in cell culture are even less susceptible to infection by subgroup C 
adenoviruses than are myoblasts. Myotubes express higher amounts of NCAM and have a 
rudimentary extracellular matrix that more closely resembles the situation in vivo (Fig.12A). 
The ability of NCAM- and α7 integrin- retargeted AdFZ33βGal to increase the gene transfer 
efficiency to human myotubes was tested. Expression of β-galactosidase in myotubes with 
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retargeted AdFZ33βGal (40 µg/ml 3C12 or 5.1H11) was 68-fold and 77-fold higher, 
respectively, than with untreated vector (Fig.12B).  
 
 
 
Fig.12 Transduction of human myotubes with NCAM- and α7 integrin retargeted AdFZ33βGal. NCAM 
expression on primary human myoblasts and myotubes was visualized by immunofluorescence with anti-NCAM 
MAb 5.1H11 (A). Antibody-mediated transduction of human myotubes. Differentiated, multinucleated myotubes 
were transduced with AdFZ33βGal (MOI=10), and with retargeted AdFZ33βGal, using 40 µg/ml anti-integrin 
α7 MAb 3C12,  and anti-NCAM MAb 5.1H11, respectively. β-Galactosidase activity was determined as relative 
light units (RLU) per 1µg total cellular protein. Each value represents the means of three parallel infections ± SD 
(B). 
 
These result demonstrates that retargeting of AdFZ33βGal to integrin α7- and NCAM surface 
proteins can be efficiently used to enhance transduction of differentiated human skeletal 
muscle cells. 
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Targteting mouse C2C12 cells. 
Since the mdx mouse is an extensively used animal model for DMD, retargeting of 
AdFZ33βGal to murine muscle cells was assessed. We used the myogenic C2C12 cell line as 
model for retargeting of AdFZ33βGal. AdFZ33βGal was retargeted to α7 integrin using 40 
µg/ml of purified anti-mouse α7 integrin MAb 6A11. The gene transfer efficiency to C2C12 
myoblasts was enhanced eight-fold (data not shown). X-Gal staining of C2C12 myoblasts 
(Fig.13A) and mixed C2C12 myoblast/myotubes (Fig.13C) after infection with integrin α7- 
retargeted virus demonstrated an increase of β-Gal positive cells.  
 
 
 
 
 
Fig.13 Retargeting of AdFZ33βGal to murine integrin α7. C2C12 myoblasts (A+B) and a mixed culture 
containing both, myoblasts and myotubes (C+D) were transduced with MOI10 of AdFZ33βGal (B+D), and 
retargeted AdFZ33βGal complexed with 40µg/ml anti-mouse integrin α7 MAb 6A11 (A+C). β-galactosidase 
activity in cells was visualized with chromogenic X-Gal substrate after 48 hours. Fig. 14C shows a mixed 
population of C2C12 myotubes and myoblasts with preferentially transduced myotubes (C). 
 
One particularly interesting finding was the selective transduction of C2C12 myotubes in the 
mixed myoblast/myotubes culture by integrin α7-retargeted AdFZ33βGal. Due to the 
inhomogeneity of the mixed cell culture, β-galactosidase activity was not quantitatively 
determined in this case. Moreover, we investigated the ability of retargeted AdFZ33βGal to a 
variety of human carcinoma cell lines, including A431, HeLa, and Jurkat cells. A summary of 
the obtained results is given in table 3. 
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Table3: Summary of results obtained with retargeted AdFZ33βGal  
Cell line 
Receptor  
targeted 
Antibody 
clone 
Targeting  
effect 
% transduced 
(10 BFU /cell) 
 
Lung carcinoma A431 
 
EGFR 
 
LA22* 
 
18 x 
 
20 % 
 
Primary human myoblasts (FHM) 
 α7 integrin  3C12  24 x  80 % 
 
FHM 
 
NCAM 
 
5.1H11 
 
37 x 
 
85 % 
 
C2C12 
 α7 integrin  6A11  8 x  ND 
 
HeLa 
 
CD3 
 
HIT3a* 
 
2 x 
 
ND 
 
Jurkat 
 
MHCI 
 
W6/32 
 
no 
 
ND 
 *For details and references the reader is referred to Thirion et al. 242.  
 
3.2.5 Specificity of antibody-mediated retargeting of AdFZ33βGal 
In order to confirm that the MAb-mediated transduction of human myoblasts cells by 
AdFZ33βGal actually required the specific binding of the MAb to the vector, and occurred via 
a CAR-independent cell entry pathway, a competitive infection assay was performed. In this 
experiment AdFZ33βGal was either preincubated with or without anti-NCAM MAb 5.1H11 
and the subsequent transduction of myoblasts cells done in the presence of 20 µg/ml 
recombinant Ad5 knob protein (KnobWT), 10µg/ml mutated (K417I, K420I) knob protein 
(KnobMUT), or 10µg/ml protein A (Protein A) (Fig.14). 
 
 
Fig.14 CAR-independent transduction of primary human myoblasts. Cells were either preincubated with 
10µg/ml Ad5 WT-knob protein (KnobWT) or 10µg/ml Ad5 MUT-knob protein without CAR binding activity 
(KnobMUT) and transduced with (MOI 10) Z33-modified vector AdFZ33βGal alone (AdFZ33βGal), or with 
AdFZ33βGal retargeted with anti-NCAM MAb 5.1H11 in the presence of Ad5 knob protein (KnobWT + 5.1H11) 
and 20µg/ml protein A (5.1H11+Protein A), respectively. β-Galactosidase activity was determined as relative 
light units (RLU) per 1µg protein and normalized to FHMs transduced with AdFZ33βGal alone (AdFZ33βGal 
=100%). Each value represents the means of three independent infections ± SD.  
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 KnobWT protein largely reduced the gene transfer efficiency of the non-retargeted vector to 
FHMs, but did not inhibit the enhanced transduction efficiency of the NCAM-retargeted 
vector (KnobWT+5.1H11), indicating that infection was largely mediated by a receptor 
different from CAR. Transduction of antibody-retargeted vector was reduced to the level of 
non-retargeted vector by competition with 20µg/ml soluble protein A. As expected, KnobMut 
protein was unable to inhibit transfection by AdFZ33βGal vector (Fig.14). 
 
 
3.3 Enhanced human muscle cell transduction by subgroup D adenovirus Ad19a  
 
3.3.1 Attachment of Ad19aEGFP to primary human myoblasts (FHM) depends on a sialic 
acid-containing receptor. 
First, the nature of cellular receptors involved in attachment of Ad19aEGFP vector to primary 
human myoblasts was investigated. Cells were pre-treated for 1h on ice with competing 
substances, then the vector was added and allowed to attach to the cells for 1h on ice. 
Thereafter, unbound virus was aspirated, the cells thoroughly washed, and transduction 
medium replaced by growth medium. EGFP expression was quantified after 48h by means of 
fluorescence measurement. Attachment of Ad19aEGFP to FHM was strongly inhibited 
(>95%) by neuraminidase and wheat germ agglutinin (WGA) (Fig.16A). Wheat germ 
agglutinin binds specifically to N-acetyl-β-(1,4)-D-glucosamine carbohydrate substrates, 
which may be a part of the carbohydrate binding epitope recognized by Ad19a. 
Neuraminidase and WGA did not affect attachment of Ad5 to FHM (data not shown). Binding 
of Ad19aEGFP was neither affected by heparin nor GRGDS. Recombinant Ad19a knob 
protein expressed in E. coli, did not affect binding of Ad19aEGFP to FHM at concentrations 
below 10µg/ml, but inhibited attachment of Ad19aEGFP >80% at higher protein 
concentrations (100µg/ml). 
To rule out any non-functionality of Ad19a knob protein expressed in E. coli, Ad19a knob 
protein was tested for its ability to trimerize under non-denaturating conditions (Fig.15A). 
Recombinant Ad19a knob protein was separated on a 10% polyacrylamide gel under 
denaturating (K19a den) and semi-native conditions (K19a nat). Proteins were visualized by 
silver staining. Interestingly, Ad19a knob protein, which contained 1.5 fiber shaft repeats, 
formed trimers, whereas the corresponding Ad5 knob protein only formed dimers under 
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similar conditions (data not shown). The purity of Ad19a knob protein preparations was 
estimated to be >90% (Fig. 15A).  To further test the receptor-binding activity of Ad19a fiber 
protein, N-terminal His6-tagged full-length Ad19a fiber protein was expressed with 
baculovirus in insect cells and affinity-purified on a Ni2+-NTA agarose column. Full-length 
Ad19a fiber proteins were separated on a 10% polyacrylamide gel under denaturating (F19a 
den) and semi-native conditions (F19a nat) and blotted on a nitrocellulose membrane. Ad19a 
fiber protein crossreacted with anti-Ad5 knob polyclonal antiserum. Fiber trimers were 
predominantly detected under semi-native PAGE (Fig.15B). 
 
  
 
 
 
Fig.15 Purification of recombinant Ad19a knob and Ad19a fiber protein. N-His6-tagged Ad19a knob protein 
was produced in E. coli strain BL21 (Startagene) and affinity-purified with Ni-NTA Agarose (Qiagen) according 
to standard protocols. Purified proteins were separated on a 10% polyacrylamide gel under semi-native (K19a 
nat) and denaturating conditions (K19a den). Protein bands were visualized by silver staining250 (A). Expression 
of full-length Ad19a fiber protein in insect cells. His6-tagged Ad19a fiber protein was purified by means of 
affinity chromatography. Purified full-length Ad19a fiber protein was separated on a 10% polyacrylamide gel 
under semi-native (F19a nat) and denaturating conditions (F19a den). Fiber proteins were transferred to a 
nitrocellulose membrane and detected with anti-Ad5 knob polyclonal antiserum (B).  
  
To test if the receptor-binding activity was located on Ad19a fiber, FHM were preincubation 
for 1h on ice with 10µg/ml purified Ad19a fiber protein and transduced with Ad19aEGFP  
(MOI=20). Ad19a full-length fiber protein efficiently decreased virus attachment by 79±2 % 
at 10µg/ml (Fig. 16A), and was able to block virus attachment completely (97±2 %) at higher 
concentrations (50µg/ml) (data not shown). This result demonstrates that the Ad19a fiber 
protein mediates binding to the cellular receptor. Therefore, it may be possible to transfer the 
receptor-binding activity from Ad19a to the better-characterized Ad5 serotype by swapping 
the fiber molecules.    
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Fig.16 Receptors involved in attachment and uptake of Ad19aEGFP vector. Primary human myoblasts were 
preincubated for 1h on ice with 10µg/ml Ad19a fiber protein, 100µg/ml Ad19a knob protein, 2mM GRGDS 
peptide, 10 µg/ml heparin, 50µg/ml wheat germ agglutinin, and 150 U /well α(2-3)-specific neuraminidase, 
respectively, and then transduced with 20 infectious viral particles per cell (20FFU added per cell) at 4°C (Ad19a 
4°C), or 37°C (Ad19a 37°C).  Transgene expression was quantified at 48 h with a fluorescence multi-well plate 
reader (A). Virus uptake-competition study: Cells were incubated with inhibiting reagents for 1h on ice and 
transduced with virus (MOI=20) for 1h at 37°C (B). Transgene expression was quantified at 48 h with a 
fluorescence multi-well plate reader and normalized to cells transduced with Ad19aEGFP alone 
(Ad19aEGFP=100%). Each value represents the means of three independent experiments ± SD. 
 
Next, we investigated which factors were involved in virus uptake. FHM were preincubated 
with competing substances for 1h at 4°C and vector added for 1h at 37°C (Fig.16B). 
Interestingly, some substances like heparin, which did not interfere with virus binding at 4°C, 
showed inhibiting activity at 37°C. Preincubation with heparin decreased transgene 
expression by 50±4.1 %. To clarify the role of αv integrins in Ad19a internalization, FHM 
were transduced with Ad19a in the presence of 2mM GRGDS peptide, resulting in a 34±4,7 
% reduction of transgene expression. Transgene expression was reduced by 74±8,9 % when 
GRGDS was combined with Heparin. In addition, transduction of myoblasts at 37°C still was 
highly sensitive to WGA and neuraminidase pretreatment (>95% inhibition) (Fig.16B). 
Binding of Ad19aEGFP to myotubes and myoblasts was very much alike. Transduction of 
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FHM-derived myotubes with Ad19aEGFP vector was completely abolished upon 
neuraminidase and WGA treatment (data not shown). 
 
3.3.2 Comparing Ad5 and Ad19a for their ability to infect muscle cells 
Comparison of two different adenovirus serotypes poses the problem of how to quantify both 
vectors in a comparable manner. Since the transduction efficiency of one cell type (e.g., 293 
cell line, which is commonly used for titration) is likely to differ between the two serotypes, 
vector genomes were determined by means of quantitative PCR223,224. We took advantage of 
the fact, that both vectors shared identical CMVEGFP expression cassettes replacing the E1 
region, and therefore amplified a 96bp amplicon from the EGFP coding region for 
quantitative PCR as previously described224,251 (Fig. 17). 
 
 
 
 
 
Fig.17 Efficiency of real time PCR for Ad vector titration. Serial dilutions of linearized plasmid pEGFP-N1 
(101 to 106 copies) were used to obtain a standard calibration curve displaying Ct values vs. copy number. 
Genomic titers of CsCl-purified virus preparations were determined using real-time fluorescence detection ABI 
Prism 7000 Sequence Detector and SybrGreen as a double-strand DNA-specific fluorescent dye.  
 
 
3.3.3 Ad19a is a human muscle cell tropic virus. 
Myoblasts of different origin, including primary mouse myoblasts, primary fetal pig 
myoblasts, primary ape myoblasts, primary fetal human myoblasts, and rat L6 myoblasts, 
were compared for their transducibility by Ad19aEGFP and Ad5EGFP, respectively. Cells 
were transduced with vector in serum-reduced infection medium over night with 1250, 2500, 
and 12500 viral genomes per cell (vg/cell), respectively, and EGFP expression quantified after 
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48h. Cells expressing EGFP (EGFP+) were counted by means of flow cytometry (table 4). 
Due to the fast proliferation of rat L6 myoblasts no FACS data was collected for this cell line.  
 
 
Table4  
Transduction efficiency in % of EGFP-expressing cells, as determined by FACS of transduced myoblasts 
 
Human 
myoblasts 
Ape 
myoblasts 
Pig 
myoblasts 
Mouse 
myoblasts 
 
Ad5EGFP 1250vg/cell 
 
43.2 % 
 
70.7 % 
 
29.2 % 
 
7.6 % 
Ad5EGFP 2500 vg/cell 59.8 % 84.6 % 42.9 % 14 % 
Ad5EGFP 12500 vg/cell 88.7 % 99.1  % 86.1 % 39.8 % 
 
Ad19aEGFP 1250 vg/cell 
 
93.4 % 
 
13.5 % 
 
2.5 % 
 
3.5 % 
Ad19aEGFP 2500 vg/cell 94 % 23.3 % 4.3 % 2.8 % 
Ad19aEGFP 12500 vg/cell 97 % 80 % 17.8 % 5.8 % 
The mean percentage of EGFP+ cells from 3 independent transduction experiments are listed. 
 
 
Strikingly, even with the 2 lower Ad19aEGFP titers used, >90% of human myoblasts were 
EGFP+, and transgene expression was 27 and 30-fold higher if compared toAd5EGFP, (Fig. 
18A). The highest transgene expression of Ad5EGFP-transduced cells was observed in ape 
myoblasts, followed by, in decreasing order, pig, human, mouse, and L6 myoblasts (Fig.18A). 
Ad5EGFP transduced ape myoblasts better than Ad19a: 99% of ape myoblasts were EGFP+ 
cells when transduced with 12500 vg/cell Ad5EGFP, compared to 75 % of EGFP+ ape 
myoblasts in the case of Ad19aEGFP. Average transgene expression was 6.6-fold higher in 
Ad5EGFP-transduced ape myoblasts than in Ad19aEGFP-transduced cells (12500 vg/cell). In 
contrast to ape and human cells, only 39.8 % of primary mouse myoblasts expressed EGFP at 
the highest vector dose used, and correspondingly, only 5.75 % of mouse myoblasts expressed 
EGFP+ when transduced with 12500 vg/cell of Ad19aEGFP. Transgene expression in primary 
mouse myoblasts was too low to be quantified with a fluorescence reader. For all titers used, 
Ad5EGFP transduced pig myoblasts better than Ad19aEGFP. 86.1 % of pig myoblasts 
expressed EGFP at the highest Ad5EGFP vector dose used, versus 17.8 % with Ad19aEGFP. 
Corresponding pictures of fluorescing EGFP-expressing cells transduced with 12500 vg/cell 
are shown in figure 18B. 
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Fig.18 Transduction of myoblasts by Ad5EGFP and Ad19aEGFP. A panel of myoblasts, including primary 
human, ape, pig, mouse myoblasts and rat L6 cells, were transduced with 1250 vg/cell (white bars), 2500 vg/cell 
(gray bars) and 12500 vg/cell (black bars), and EGFP expression quantified at 48h. Each value represents the 
means of three independent experiments ± SD (A). Pictures of fluorescent cells transduced with 12500 vg/cell 
were recorded 48h post transduction with a Leica DMRBE epifluorescence microscope equipped with AxioCam 
HRC and analyzed with AxioVision 3.1 software (Zeiss, Jena, Germany). Recording time was generally 5s, 
except for strongly expressing ape myoblast (Ad5 panel), and human myoblasts (Ad19a panel), where the 
recording time was limited to 1s (B).  
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3.3.4 Differential muscle cell transduction efficiencies of Ad5EGFP and Ad19aEGFP 
evaluated by quantitative real time PCR  
In order to find out whether the observed variable gene expression was due to differentially 
regulated gene expression or due to a more efficient delivery of viral genomes, adenovirus 
genomes were quantified by real time PCR in transduced cells 48h post transduction (Fig.19). 
Care was taken to eliminate residual surface-bound viral particles before DNA extraction by 
applying several washing steps. Adenovirus DNA was isolated as previously described and 
equal amounts of DNA used in each PCR reaction. The determined genomic EGFP copy 
number (equivalent to virus genome number) correlated well with transgene expression in 
cells for both vectors (fig.19 and table 5). It may be concluded, that differences in transgene 
expression are attributed to differences occurring during virus uptake and intracellular 
transport. Two additional parameters, addressing the transduction efficiency (% of initially 
applied viral genomes detected at 48h), and EGFP expression activity (particles required per 
relative fluorescence unit [RFU]) were considered. Most of the values were in accordance 
with the expected results, though derivations occurred especially for the highest Ad19aEGFP 
vector dose used. Those derivations are highlighted in red in table 5. First parameter analyzed: 
In theory, the percentage of vector genomes detected 48h post transduction reflects the 
transduction efficiency and should be constant for all titers used, assuming vector binding and 
uptake under non-saturating conditions. In agreement with low EGFP expression, low 
amounts of vector genomes were found in primary mouse myoblasts and L6 cells. The 
amount of detected vector genomes increased proportionally to EGFP expression in pig, ape, 
and human myoblasts. However, it should be emphasized that very high amounts of initial 
Ad19aEGFP vector genomes ranging from 3.94% to 6.59% were detected in human 
myoblasts, whereas only 0.096% to 0.132% of the initial vector genomes could be detected in 
FHMs transduced with Ad5EGFP. This result reflects the extremely efficient uptake of 
Ad19aEGFP virus by primary human myoblasts. Two prominent derivations were observed in 
ape and pig myoblasts transduced with 12500 vg/cell Ad19aEGFP. Here, a disproportionate 
increase of cell-associated vector genomes was observed, which did not correlate with 
transgene expression. This disproportionate increase in vector genomes may be attributed to 
either inefficient downstream events occurring after vector endocytosis (e.g. mislocalization 
of the vector), or to species-dependent differential promoter regulation.  
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Fig.19 Correlation of intracellular vector genomes and transgene expression. Myoblasts were transduced 
with 12500 vg/cell and the total EGFP copy-number per 5x104 transduced cells determined by real time PCR. A 
serial dilution of linearized plasmid pEGFP-N1(101 to 106 copies) was used to obtain a standard calibration 
curve. The virus genome copy numbers were adjusted by factor 10-2 (Ad5EGFP genome copy number), and 10-3 
(Ad19aEGFP genome copy number), respectively, to fit the relative fluorescence unit scale. Values represent the 
means of three independent experiments. 
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Table 5:  
Cell line Virus Vg/cell [RFU]
 
Total vg 
by real 
time PCR 
% vg 
detected
Particle/ 
RFU 
Vg/cell* 
FHM MB Ad5 1250 148 59962 0,096 405 1,2 
 Ad5 2500 457 131737 0,106 240 2,6 
 Ad5 12500 3997 818603 0,132 205 16,4 
 Ad19a 1250 11594 4120312 6,59 355 82,4 
 Ad19a 2500 20139 5198988 4,16 258 103,9 
 Ad19a 12500 30542 24640027 3,94 807 492,8 
        
Ape MB Ad5 1250 1738 208963 0,330 120 4,2 
 Ad5 2500 3538 363869 0,291 103 7,3 
 Ad5 12500 16960 1896097 0,303 112 37,9 
 Ad19a 1250 0 123802 0,199 - 2,5 
 Ad19a 2500 83 224492 0,180 2705 4,5 
 Ad19a 12500 2557 5573543 0,892 2180 111,5 
        
Pig MB Ad5 1250 772 64439 0,103 83 1,3 
 Ad5 2500 1475 106556 0,085 72 2,1 
 Ad5 12500 6857 436480 0,070 64 8,7 
 Ad19a 1250 0 18881 0,030 - 0,38 
 Ad19a 2500 37 21043 0,016 569 0,42 
 Ad19a 12500 419 1212229 0,194 2893 24 
        
Mouse MB Ad5 1250 0 9649 0,015 - 0,19 
 Ad5 2500 0 22760 0,018 - 0,46 
 Ad5 12500 0 81540 0,013 - 1,6 
 Ad19a 1250 0 9409 0,015 - 0,19 
 Ad19a 2500 0 20863 0,017 - 0,42 
 Ad19a 12500 0 18126 0,003 - 0,36 
        
Rat L6 Ad5 1250 0 15978 0,026 - 0,32 
 Ad5 2500 0 ND ND - ND 
 Ad5 12500 0 94428 0,076 - 1,9 
 Ad19a 1250 0 8053 0,013 - 0,16 
 Ad19a 2500 0 ND ND - ND 
 Ad19a 12500 0 25454 0,004 - 0,51 
        
* In order to allow for optimal transgene expression, cells were kept in growth medium supplemented with 
10% fetal bovine serum during the entire experiment (48h). 
 
 
The particle per RFU ratio describes the activity of the EGFP-expression cassette per cell-
associated viral particle. In theory, the intracellular localization of viral particles, the 
uncoating efficiency, nuclear import of adenoviral DNA, vector-related toxicity, and species-
dependent regulation of CMV / adenovirus ITR enhancer elements may affect the 
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transcriptional activity of the virus-encoded EGFP expression cassette. Remarkably, the 
particle/RLU ratios were several times higher for Ad19aEGFP (12500 vg/cell) than for 
Ad5EGFP in human (3.9-fold), ape (19.5-fold), and pig myoblasts pig (45-fold).  
 
3.3.5 Lack of maturation-dependent decrease for transfection of myotubes 
We next tested the ability of both vectors (Ad5EGFP and Ad19aEGFP) to transduce fully 
differentiated myotubes derived from human and ape myoblasts. Consistent with previously 
reported data252, Ad5EGFP transduced human myotubes several times less efficient than 
myoblasts. On the other hand no differentiation-dependent decrease of transduction was 
observed with Ad19aEGFP. Gene expression in human myotubes transduced with 
Ad19aEGFP was 20-fold, as compared to Ad5EGFP (Fig.20A). 
 
 
 
 
 
Fig.20 Transduction of ape and human myotubes by Ad5EGFP and Ad19aEGFP. Myotubes derived from 
primary human and ape myoblasts were transduced with 1250 vg/cell (white bars), 2500 vg/cell (gray bars) and 
12500 vg/cell (black bars), and EGFP expression measured at 48h. Each value represents the means of three 
independent infections ± SD (A). Pictures of fluorescent cells transduced with 12500vg/cell were recorded 48h 
post transduction with a Leica DMRBE epi fluorescence microscope equipped with AxioCam HRC and analyzed 
with AxioVision 3.1 software (Zeiss, Jena, Germany). Recording time was 5s, except for strongly expressing ape 
myotubes (Ad5 panel), where the recording time was reduced to 1s (B). 
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In contrast to human muscle cells, gene transfer efficiency in ape myoblasts and myotubes 
was higher for Ad5EGFP (12500vg/cell), resulting in 19-fold and 5-fold increase, 
respectively, of transgene expression as compared to Ad19aEGFP. Surprisingly, no 
maturation-dependent decrease in gene transfer efficiency was observed with ape myotubes 
transduced by Ad5EGFP. 
 
3.3.6 Transduction of primary human cells by Ad19aEGFP. 
Next, we compared the ability of Ad5EGFP and Ad19aEGFP to transduce primary human 
cells of potential interest for gene therapy. Primary human monocyte-derived immature 
dendritic cells (DC), epithelial cells (HUVEC) and smooth muscle cells (SMC), were 
transduced with 1250 vg/cell, 2500 vg/cell, and 12500 vg/cell Ad5EGFP and Ad19aEGFP, 
respectively, and transgene expression quantified after 48h. Smooth muscle cells were 
preferentially transduced by Ad19aEGFP whereas HUVEC cells were better transduced by 
Ad5EGFP (Fig. 21A). Monocyte-derived immature human dendritic cells are target cells in 
many immunization protocols and unwanted transduction of tissue DCs after gene transfer 
was reported to trigger the anti-adenovirus immune response. Peripheral blood monocyte cells 
(PBMCs) were isolated from healthy donor blood and monocytes differentiated in medium 
containing GM-SCF and IL4. Surface expression of DC-specific markers was characterized at 
day 7. 46% of differentiated monocytes expressed DC-specific markers CD11c and DC-SIGN 
(data not shown). Surprisingly, the percentage of EGFP-expressing DCs, transduced with 
Ad5EGFP or Ad19aEGFP, respectively, was equal for both vectors (Fig.21B), but levels of 
transgene expression were 10- to 25-fold higher in Ad19aEGFP-transduced DCs (Fig.21A). 
Since both vectors use αv integrins for internalization, one explanation may be, that both 
vectors transduced the same subset of cells. Moreover, the transduction efficiency may be 
higher for DCs transduced by Ad19aEGFP vector as compared to Ad5EGFP, and thus explain 
the observed higher transgene expression.  
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Fig.21 Transduction of target cells for gene therapy with Ad5EGFP and Ad19aEGFP. Primary human cells, 
including primary smooth muscle cells, human umbilical vein endothelial cells (HUVEC), and immature 
monocyte–derived dendritic cells were transduced with 1250 vg/cell (white bars), 2500 vg/cell (gray bars), and 
12500 vg/cell (black bars), and EGFP expression quantified after 48h. Each value represents the means of three 
independent infections ± SD (A). FACS analysis of CD11c-positive DCs transduced with 12500vg/cell reveals 
equal numbers of EGFP-expressing cells for DCs transduced with Ad5EGFP and Ad19aEGFP, respectively, but 
a marked increase in the fluorescence intensity with cells transduced by Ad19aEGFP, as compared to 
Ad5EGFP(B).  
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4. Discussion 
 
4.1 Overcoming the hurdles in adenovirus-mediated gene delivery in vivo  
  
An ideal viral vector for gene therapy should have the following attributes: it should take 
advantage of the cellular uptake and intracellular transport machinery and efficiently deliver a 
gene of interest to the nucleus, it should be non-immunogenic, show persistent and stable gene 
expression, it should be able to package large cDNA constructs, and it should infect only the 
tissue of choice. In order to achieve this, great effort must be undertaken to find solutions for 
each of the above-mentioned goals. Since differentiated human muscle cells express 
insufficient levels of primary adenovirus attachment receptor, CAR, and hence are relatively 
resistant to transduction by adenovirus serotype 5, we focussed on the development of virus 
retargeting to alternative muscle-specific receptors with the aim of simultaneously increasing 
specificity and transduction efficiency of human muscle cells. Milestones achieved in the 
development of low-immunogenic and long-term gene expression with adenovirus gene 
therapy vectors will be discussed first.    
 
4.1.1 Development of low-immunogenic adenovirus gene therapy vectors   
Seropositivity for Ad5 and Ad2 in European populations is highly prevalent, and may 
severely impair vector administration or readministration in gene therapy applications140. 
Although clearance of adenovirus by neutralizing antibodies is an important factor, other 
components, e.g. cells of the reticular endothelial system (RES) and opsonizing serum factors, 
interact with Ads as well, and have to be taken into consideration as potential inhibiting 
factors, especially when gene transfer is done via blood circulation. Development of “stealth” 
adenoviruses by means of chemical modification of the capsid with polymers may be a 
promising way to shield viral particles from those factors and increase stability and blood 
circulation properties253. Recently, two polymer-modifications, based on polyethylene glycol 
(PEG) and hydrophilic poly-N-(2-hydroxypropyl)-methacrylate (pHPMA), respectively, have 
been used to coat adenoviral vectors139,254. Targeting ligands like the basic fibroblast growth 
factor (bFGF) can be incorporated into the pHPMA polymer coat and mediate transduction to 
bFGFR-positive cells. Vector shielding may also be advantageous for blunting the unspecific 
uptake of adenoviral particles by liver macrophages (Kupffer cells), since at least opsonizing 
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serum components do not bind to hydrophilic polymer coats and PEGylation reduces blood 
clearance rates, which normally lead to clearance of >99% of adenoviral particles within 
1h176,177. Reduced uptake of Ad by Kupffer cells (and other tissue macrophages) may also 
reduce the generation of a humoral immune response against virus-encoded transgenes. 
Expression of AAT under the control of a liver-specific promoter resulted in absence of anti-
AAT-1 antibodies after hepatic gene transfer136. 
 
4.1.2 Long-term transgene expression and site-specific gene integration into human 
chromosomes  
Stable integration of genes into a defined chromosomal locus can be achieved with 
homologous recombination, but occurs with a low frequency of approximately 10-6 in 
multicellular organisms255. Several microorganisms, however, provide enzymes that mediate 
integration and excision of genes at specific target sites in eukaryotic cells without the need 
for bacterial co-factors. Cre, and Flp recombinases perform both integration and excision of 
genes at target sites, though the excision reaction predominates and net-integration frequency 
is 0.03% for Cre recombinase256,257. If exclusive integration is required, other types of 
recombinases, like the integrase from Streptomyces phage ΦC31 may be better suited, since 
ΦC31 recombinase catalyzes unidirectional integration of genes between phage attachment 
sites (attP) and bacterial attachment sites (attB)258. Site-specific integration of genes in 
eukaryotic cells following recombination between attB and attP sites has been achieved, and 
used to express therapeutic levels of factor IX (FIX), resulting from stable integration of the 
FIX gene in chromosomal pseudo-attP sites259,260. A study, aimed to investigate site-specific 
integration of attB-containing plasmids into chromosomal pseudo attP sites, revealed 31 
different chromosomal pseudo attP sites in 293A cells with high prevalence of integration to a 
particular site, termed pseudo attP site A261. It is thus conceivable to direct gene integration 
into such sites, which may reduce the risk of insertional mutagenesis, as occurring with 
randomly integrating retroviral vectors. A similar strategy was recently employed to stabilize 
gene expression in vivo with a high-capacity adenovirus-transposon vector262. In another 
attempt to stabilize transgene expression after adenovirus gene transfer, episomal maintenance 
of circularized adenoviral genomes containing Eppstein-Barr virus OriP/EBNA-1 locus was 
demonstrated263.  
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 4.1.3 Retargeting or detargeting?  
The K417I, K420I double point mutation within the CAR-binding AB loop, which was 
characterized in the present work, led to almost complete loss of CAR-binding. The K417I, 
K420I point mutations lead to CAR-detargeting with comparable efficiency to the most potent 
mutations previously described, e.g., Y477A, and S408E174. However, Alemany et al. 
demonstrated that ablation of the CAR-binding activity alone did not change the 
biodistribution pattern when Ad5 was injected intravenously176. Removal of the natural 
tropism of Ad5 was shown to require combined removal of CAR and integrin αv-binding 
within the penton base182. Maximal removal of the CAR-binding activity through introduction 
of multiple point mutations within the AB loop (R421S, A415G, E416G, and K417G) only 
marginally affected transgene expression in skeletal muscle, whereas administration of CAR 
and integrin double-ablated mutant vectors decreased luciferase expression by about 100-fold 
and the number of delivered genomes by 15-fold182. Similar results were obtained after 
intravenous administration of CAR-ablated vector mutants to other organs. Double-ablated 
viruses transduced all tissues lower by up to 700-fold. CAR-ablation alone led to decreased 
transgene expression in liver only. Hepatocytes express high levels of CAR, which may be 
accessible, in contrast to CAR in heart tissue, where CAR may be confined to cell-cell 
junctions. Based on these results one can conclude that reducing the native tropism is 
synonymous with complete loss of integrin αv-binding ability. Introduction of a new targeting 
moiety thus not only has to provide cell attachment, but also has to target internalization for 
effective transduction. This strategy may limit the choice of a targeting ligand and confine 
retargeting of double-ablated vectors to internalization-promoting receptors and pathways. 
 
4.1.4 Genetic retargeting of adenovirus using the protein A-derived antibody-binding domain 
Z33   
In this work, a versatile strategy for retargeting of Ad-vectors, based on the incorporation of 
an IgG-binding peptide into the capsid and allowing for the use of unmodified monoclonal 
antibodies to redirect the vector to specific cell surface molecules, was developed. The Z33-
domain was incorporated into the HI-loop of the fiber knob where it retained high-affinity 
IgG-binding activity.  
Using surface plasmon resonance measurements, the binding affinity of KnobZ33 protein to a 
mouse MAb was determined to be KD = 2.4 nM, suggesting that the binding affinity of Z33 in 
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the context of the knob domain was in the same range than the affinity of Z33 and the full-
length Z-domain polypeptides to IgG1 immunoglobulins, which are KD(Z33) = 43 nM and 
KD(Z) = 10 nM, respectively243. However, our measurements were performed with a BIAcore 
sensor chip carrying immobilized mouse IgG2a in contrast to the human IgG1 that was used in 
the original experiment. The Z33-domain, which is a 33-aa-long double-helix version of the 
59-aa long triple-helix Z-module derived from staphylococcal protein A243,264,265, may 
potentially have been stabilized by either flanking aa residues or the tertiary structure of the 
knob domain. In addition, the homotrimeric nature of the fiber knob carrying three Z33-
domains per molecule most probably accounts for the higher overall affinity to IgG2a in the 
BIAcore experiments, as opposed to the monomeric peptide. Insertion of Z33 into the knob 
domain did not significantly affect CAR binding. BIAcore affinity measurements using a 
soluble CAR protein as analyte for binding to immobilized Knob and KnobZ33, respectively, 
yielded similar binding rate constants (ka and kd). In accordance to this result, the modified 
vector AdFZ33βGal could be readily propagated on CAR-expressing producer cells. The 
dissociation constants obtained for interaction between sCAR (extracellular part of CAR, 
containing both extracellular domains D1 and D2) and the knob proteins were high as 
compared to values previously reported by others for association of the CAR D1-domain 
alone with wild-type knob protein (KD = 25 nM)266, and binding of full-length fiber protein to 
CAR-expressing cells in vitro (KD = 2 nM)9. This could potentially be due to a modifying or 
masking effect of the D2-domain in our recombinant sCAR protein on the knob binding site 
in the D1-domain which might not be exerted if D1 is expressed alone or the full-length CAR 
protein is anchored to the cellular membrane. True retargeting of Z33-modified AdFZ33βGal 
to non-CAR receptors was demonstrated, since recombinant knob protein failed to compete 
with NCAM-retargeted viruses for binding receptors (Fig.15). Experiments with EGFR-
retargeted AdFZ33βGal confirmed this result and demonstrated that only protein A was able 
to compete for antibody binding and to ablate the enhanced retargeting efficiency of 
AdFZ33βGal242. Knob protein (KnobWT) was not able to inhibit transduction of FHMs with 
NCAM-retargeted AdFZ33βGal. These results raise the question of whether introduction of 
CAR-detargeting mutations are necessary to increase specificity of antibody-retargeted 
AdFZ33βGal. The gene transfer efficiency was enhanced 2-fold in an unspecific way upon 
preincubation of AdFZ33βGal with high concentrations (up to 40µg/ml) of p53 control 
antibody. This result may be explained by some weak residual binding activity of p53 to cell 
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surface proteins, but remained moderate if compared to the specific increase (up to 37-fold) 
with integrin α7 and NCAM-retargeted AdFZβGal33242. We tried to enhance the gene transfer 
efficiency to Jurkat and HeLa cells using CD3-, and MHCI-retargeted AdFZ33βGal, but 
achieved only minor effects. Similarly, ligand screening with metabolically biotinylated 
adenoviral vectors for enhanced transduction of bone-marrow-derived dendritic cells yielded 
variable transduction efficiencies that were strongly dependant on the targeted receptor281. In 
contrast to our results, highly efficient and specific transduction of primary resting T-cells was 
achieved with CD3-retargeted adenovirus. In this study a bispecific antibody consisting of an 
anti-FLAG MAb chemically crosslinked to anti-CD3 MAb (different from the anti-CD3 MAb 
used in this work) was used to retarget a penton-base-modified adenovirus to the CD3 
receptor209. This result demonstrates that the choice of the retargeting antibody is essential for 
successful retargeting of adenovirus vectors.   
A general concern related to the use of antibody-retargeted viruses is that there could be 
unwanted activation of the complement system, which may occur if free antibodies are co-
injected with the virus, or if antibodies dissociate from the virus during prolonged circulation 
times. To minimize unwanted side effects, it may therefore be necessary to remove unbound 
antibodies prior to vector application in vivo, or to attach the targeting antibodies covalently to 
the virus.  
 
4.1.5 Genetic retargeting of adenoviral vectors and the choice of the targeting ligand and 
insertion site 
This work demonstrates that the insertion capacity of the HI loop can be expanded to larger 
ligands. In a recent study, the insertion capacity of the HI loop was systematically analysed 
and the entire RGD-loop from adenovirus penton base (83aa) inserted267. Interestingly, the 
insert size only moderately affected titres of recombinant vectors, though functionality of the 
inserted RGD sequence was size-dependent. The adenovirus structural proteins are 
synthesized in the cytosol and thereafter translocated into the nucleus, where adenoviral 
particles are assembled268. The cytoplasmic expression of fiber molecules narrows the choice 
of targeting ligands to ligands that do not need disulfide bonds for correct folding and 
solubility.  A strict correlation between solubility of chimeric fiber proteins and viability of 
virus was observed with genetically retargeted knobless adenoviral particles. Rescue of fiber-
modified adenovirus vectors with a single-chain antibody fragment (scFv) and fibroblast 
growth factor (FGF), respectively, was not achieved269. Based on these findings, the method 
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of producing retargeted knobless Ads was improved by fusing cytoplasmically stable 
antibodies, termed “affibodies” to the fiber protein C-terminus consisting of 7 adenovirus 
shaft repeats followed by a spacing trimerization domain from lung surfactant protein200. One 
disadvantage of using knobless affibody-targeted vectors is the high genome-to-infectious 
virus ratio, which is in the range of 1:118 to 1:421, and may be disadvantageous for the use of 
these vectors in vivo200. Insertion of the Z33 ligand into the HI loop, which functionality did 
not rely on expression via the secretory pathway or disulfide bond formation, resulted in 
expression of soluble Z33-, and Z34C-modified fiber proteins, respectively, and rescue of 
viable Z33-mofifiend vector. We were unfortunately not able to rescue the corresponding 
adenovirus with Z34C HI-loop insertion, though Z34C-modified fiber protein (FZ34C) was 
soluble and trimerized, as shown by Western blot analysis of CV-1 cells transduced with 
FZ34C-producing vaccinia virus (Fig.8A). Due to the required formation of a disulfide bond, 
degradation of partially folded Z34C fiber protein may be a likely explanation for the failed 
virus rescue. An adenovirus vector with functional extension of the fiber protein C-terminus 
with an engineered 70 aa biotin acceptor protein (BAP) was rescued. When the same ligand 
was introduced into the HI loop, no viable virus could be obtained281. This example 
demonstrates the importance of a careful ligand design and choice of the appropriate insertion 
site in order to obtain viable vectors. 
Apart from the HI-loop, targeting ligands were successfully inserted into adenovirus protein 
IX and penton base protein204,205,206. Extension of the C-terminus of pIX with the large 
heterologous proteins EGFP and long targeting ligands have been reported and make this 
protein very attractive for adenovirus retargeting206.   
 
4.1.6 Methods to increase high-affinity binding of targeting ligands to targeted molecules  
Phage display is a powerful tool for screening large populations of targeting ligands. Tissue-
specific binding ligands were identified by panning a complex bacteriophage library and 
successfully used for vector retargeting191,270. One major disadvantage of small targeting 
peptides is their often-weak affinity to target structures and their lack of structural rigidity. 
One of the most potent ligands ever selected was the ACDCRGDCFCG (RGD-4C) peptide, 
which has a strong affinity to αv integrins271. Originally isolated from a phage-displayed 
peptide library screened for specificity for αvβ5 integrin, RGD-4C was shown to be a potent 
binder (affinity constant of ~100 nM) of αvβ3 and αvβ5 integrins. Both integrins are 
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selectively expressed in angiogenic vasculature and direct RGD-4C-retargeted adenoviruses to 
tumor cells272,190. Improvement of avidity and structural rigidity of selected ligands has been 
achieved using a constrained combinatorial library of 20-residue peptides displayed by the 
active site loop of E. coli thioredoxin. The selected peptide aptamers were able to bind their 
target with high affinity in the nanomolar range273.  
In another approach, context-specific peptide-presenting phage libraries have been generated 
using an adenovirus HI-loop phage display system to mimic the expression of peptides in the 
viral context. The context-specific peptide library approach is an attractive system to screen 
even large peptide inserts, circumventing toxicity-related problems with knob-expression 
libraries or the low complexity of viral libraries274. Since modifications of viral capsid 
proteins can affect the viability of a virus, creating an infectious retargeted virus vector library 
may allow for efficient screening of tissue-specific viruses in vivo and bypass in vitro 
selection. A surface-exposed loop structure was chosen as the site of incorporation for a 
complex peptide library and used to create an AAV-based virus library275,276. Similarly, other 
virus-based libraries have been generated and used to identify retargeted virus vectors277,278. 
A high affinity linkage is required if virus vectors are retargeted by means of adaptor 
molecules or antibodies. Several very high affinity ligand-receptor interactions, like barnase-
barnstar complex with KD = 10-14 M, and biotin streptavidin complex (KD = 10-15 M), have 
been described279,280. The latter concept was recently used for adenovirus and AAV 
retargeting by incorporating a small biotin-binding peptide to the C-terminus of fiber protein 
capsid allowing for metabolic biotinylation in 293 cells281.  
 
4.1.7 Perspective for muscle-specific targeting of adenoviral vectors 
Though the use of a genetically engineered AdV with a C-terminal poly-lysine moiety 
enhanced gene transfer into mouse skeletal muscle in vivo, these vectors still transduce many 
other cell types as well. The development of retargeted and muscle-specific AdV is highly 
desirable for therapeutic use. Potential ligands, i.e., muscle-specific peptides, have been 
selected by different methods such as phage-display270,282. Their ability to enhance AdV-
mediated gene transfer upon genetic engineering of Ad shall be evaluated in the future.  
Low CAR and αvβ3 integrin expression levels limit adenovirus-mediated gene transfer to 
adult skeletal muscle151,155. To date, only a few muscle-specific and sufficiently expressed 
surface markers have been characterized that could be used for genetic retargeting of viral 
vectors282. One example is the Fe-transferrin receptor that is overexpressed in regenerating 
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muscle fibers283. Integrin α7β1 is an excellent candidate for muscle-specific vector targeting, 
since the integrin α7 subunit is almost exclusively expressed in skeletal, smooth and cardiac 
muscle, and is increased on the surface of muscle fibers in DMD patients and mdx 
mice248,284,285. Another promising target receptor is NCAM, which is expressed in activated 
satellite cells and myogenic precursor cells during regeneration247,286. The concept of targeting 
regenerating and newly forming myofibers and muscle satellite cells ("targeting the next 
generation") may prove particularly useful for young patients with limited fibrosis. In this 
study it was demonstrated that both integrin α7β1 and NCAM could serve as attachment 
receptors for retargeted adenovirus vectors and promoted their internalization in myoblasts as 
well as in differentiated myotubes. Augmentation of the transduction efficiency of myotubes 
by integrin α7β1- and NCAM-targeted AdFZ33βGal up to 77-fold is of particular interest for 
further development of an Ad-vector-based gene therapy of muscular dystrophies. Since 
myotubes cultivated in vitro have a rudimentary extracellular matrix287 and are difficult to 
transduce with adenovirus, they may well reflect the behaviour of muscle fibers in vivo252. 
One hallmark of dystrophic muscles of DMD patients is the high prevalence of regenerating 
fibers, in conjunction with an altered expression profile of several muscle-specific proteins288.  
At birth, ~30% of the sublaminar mouse muscle nuclei are satellite cells, decreasing to less 
than 5% in a 2-month-old adult mouse289. Alternative “targetable” receptors in quiescent 
satellite cells may be the c-Met receptor290 (receptor for hepatocyte growth factor) as well as 
M-cadherin286, which are activated in response to stimuli such as stretching, exercise, injury, 
and electrical stimulation (reviewed in289).  
 
4.2 Exploiting the natural adenovirus serotype pool. 
4.2.1 Infectious pathway of adenovirus serotypes 5 and 19a in primary human muscle cells 
A combination of heparin, knob, and soluble GRGDS peptide was necessary to efficiently 
inhibit binding of Ad5EGFP to primary human myoblasts. Soluble GRGDS peptide, an 
inhibitor of αvβ3 integrin function, had no effect on vector binding but affected transduction at 
37°C, confirming that αvβ3 is involved in virus internalization rather than in virus binding9. In 
agreement with the proposed two-step model for Ad5 cell transduction, additive inhibitory 
effects of GRGDS peptide and Ad5 knob, and GRGDS and heparin, respectively, occurred at 
37°C, at which point virus internalization is promoted, but not at 4°C, which is a non-
permissive temperature for virus internalization7,9. Taken together these results agree with 
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previous findings, while also demonstrating the importance of alternative receptors like 
heparansulfate proteoglycans for Ad5 binding and transduction23,24,25. Binding of Ad5 to CAR 
is crucial for transduction of fetal muscle in vivo291, and the maturation-dependent decrease in 
transduction efficiency may be a consequence of the accompanying reduction of CAR and 
alpha v integrins in mature versus newborn muscles151. In contrast, support for the relevance 
of non-CAR-mediated liver transduction came from experiments with detargeting mutations 
in the putative HSG-binding motif within the Ad5 shaft, which reduced hepatic gene transfer 
in vivo175. Moreover, additional HSG-binding sites, that did not overlap with the CAR-binding 
region were mapped within the Ad5 knob292. The current understanding of subgroup C 
adenovirus endocytosis involves initial clathrin-mediated endocytosis induced by interaction 
of penton base with integrin αvβ3 followed by αvβ5-integrin–mediated endosomal membrane 
permeabilization and endosome escape. The Ad2 penton base has a propensity to bind to 
nonionic detergents at low pH, suggesting that membrane-reactive hydrophobic regions may 
be exposed in acidified early endosomes293. Since Ad2 penton base alone did not increase 
membrane permeabilization, which is a prerequisite for virus escape, it was proposed that 
other viral/host factors could be involved294.  
Interestingly, adenovirus protein IIIa exhibits a basic sequence located near the C-terminus 
with homology to vitronectin and HIV Tat basic region, which were shown to bind to integrin 
αvβ5 in an RGD-independent way (figure 23)295.  
 
C K K Q R -- F R H R 
T R R Q R H D R Q R 
K R R Q R -- R R -- -- 
Vitronectin (VN) basic region: 
Protein IIIa VN-homologue region: 
HIV-Tat basic αvβ5 binding region : 
 
Figure 23: Alignment of the basic αvβ5-binding 
sequences from vitronectin, Ad5 protein IIIa, and 
HIV-1 Tat. Conserved homologous amino acids 
are highlighted in yellow. 
 
Moreover, analysis of the primary amino acid sequence from Ad5 fiber gene reveals the 
presence of a functional N-terminal NPXY sequence. The 11NPVY14 motif together with the 
N-terminal Ad5 fiber nuclear localization signal 1AKRARLSTSF10 promoted nuclear 
transduction of plasmid DNA condensed by a poly-lysine moiety296.  The NPVY motif 
enhanced transfection up to 30-fold. A conserved NPXY motif is found in many β integrin 
subunits and was shown to function as a coated pit localization signal297,298. In addition to the 
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functional RGD motif, the Ad5 penton base contains 6 conserved NXXΦ sequences that may 
also be involved in endocytosis299. Indeed, adenovirus-like particles termed adenovirus 
dodecahedron, composed solely of Ad3 penton base protein or Ad3 penton base protein and 
fiber protein enter cells efficiently via endocytosis and accumulate at the nuclear 
membrane300. 
 
 
The infectious pathway of adenovirus serotype 19a 
Soluble GRGDS peptide had no effect on Ad5EGFP and Ad19aEGFP vector binding, but 
reduced the transfection efficiency at 37°C, suggesting that αv-integrins are involved in virus 
uptake of both serotypes. Attachment of Ad19aEGFP vector to FHM at 4°C was completely 
blocked by WGA or neuraminidase. Therefore, Ad19aEGFP may specifically recognize a 
carbohydrate epitope containing α(2,3)-linked sialic acid and N-acetyl-β-(1,4)-D-
glucosamine. Heparin and GRGDS peptide did not interfere with the binding of Ad19aEGFP 
to muscle cells at 4°C, but reduced the gene transfer efficiency at 37 °C. A two-step model for 
Ad19aEGFP, similar to Ad5, with separate receptors involved in virus binding and uptake, 
may therefore be conceivable. Furthermore, heparin and GRGDS may be competing for 
binding sites on a putative internalized co-receptor. Indeed, the presence of a conserved 
putative integrin-binding RGD motif within Ad19a penton base protein may explain the 
sensitivity of virus internalization to soluble GRGDS peptide6. A role for heparin-binding 
receptors in Ad19a internalization has not been reported prior to this study.  
  
4.2.2 Tropism of Ad19a-based recombinant vector 
Subgroup D adenovirus serotypes Ad37, Ad19, and Ad8 have ocular tropism and infect 
conjunctival cells via sialic acid containing receptors but not CAR-expressing lung epithelial 
A549 cells5,6,301. The natural occurring complexity of adenovirus receptors, as reflected by 
association of different subclinical symptoms with different adenovirus serotypes, could be 
well exploited for vector development. A previously reported Ad35-based vector transduced 
monocyte-derived immature dendritic cells, smooth muscle cells and synoviocytes more 
efficiently than did Ad5140. Similarly, the novel subgroup D adenovirus type 19a vector 
transduced primary human cells, including dendritic cells, smooth muscle cells, primary 
human myoblasts, and otherwise difficult-to-transduce myotubes better than did the 
corresponding Ad5-based vector. Ad19a seems to be particularly well adapted to human 
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muscle cells because even at low vector doses (1250 vg/cell) more than 90% of myoblasts 
expressed the transgene. Moreover, immature monocyte-derived dendritic cells (positive for 
CD11c marker) that were transduced by Ad19aEGFP expressed several-fold-higher levels of 
EGFP than did DCs transduced with Ad5EGFP. Accordingly, Ad19a-based vectors may be 
suited for vaccination.   
The tropism of one adenoviral serotype can be transferred to another by swapping the entire 
fiber molecules or the distal fiber knob domains195,302. Systematic analysis of fiber-chimeric 
Ad5-based vectors led to the identification of 3 chimeric vectors (Ad5.Fib16; Ad5.Fib35, and 
Ad5.Fib50) that showed enhanced transduction of human primary cells and established cancer 
cell lines302,303,304. Similar to these chimeric vectors, an Ad5.Fib19a vector may display the 
same tropism as the Ad19a-based vector. Sequestration of CAR in basolateral membrane 
adherens junctions of polarized airway epithelial cells is thought to preclude Ad5-mediated 
gene transfer and successful delivery of CFTR cDNA in well-differentiated airway epithelium 
cells305. Unlike with Ad5 and AAV-2, the airway epithelium can be efficiently transduced 
with AAV-5, which binds to apically-expressed receptors containing α(2-3)-linked sialic 
acid306,307. Similarly, Ad19a-derived vectors may be suited for gene transfer to the airway 
epithelium and prove useful in studies aimed to investigate whether extracellular barriers or a 
shortage of viral receptors on the apical surface are limiting transduction of airway 
epithelium. In a very recent publication CD46 was identified as primary attachment receptor 
for Ad37 on human cervical carcinoma and conjunctival cells308. Since Ad19a and Ad37 fiber 
have identical primary protein sequences, and since the Ad5 vector pseudotyped with Ad37 
fiber protein (Ad5.F37) also bound CD46, it is likely that Ad19a also uses CD46 as primary 
receptor308.   
 
4.2.3 Inter-species differences for viral transduction 
One surprising finding was the strong transduction of undifferentiated as well as differentiated 
ape skeletal muscle cells by Ad5 without a noticeable differentiation-dependent decrease in 
gene transfer efficiency, which is in contrast to observations in human cells. Moreover, both 
serotypes showed significantly lower transduction of rat L6 and primary mouse myoblasts. 
The low transduction efficiency of rat L6 cells and primary mouse myoblasts reflects the poor 
performance of Ad5 in vivo after direct intramuscular injection in adult mice147. Similar 
species-dependent variations in gene transfer and expression were observed in a dose-
response study with SMCs derived from carotid arteries of different species. As opposed to 
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monkey and rabbit, the mouse, pig, and human SMCs were less susceptible to Ad5. 
Differences in attachment, internalization and intracellular trafficking of Ad5 may occur 
among other species. A vector displaying the Ad16 fiber molecule on an Ad5 backbone 
(Ad5.Fib16) preferentially transduced monkey and human SMCs, but only poorly transduced 
SMCs of pig, rat, rabbit, and mouse origin302. Strikingly, Ad5 transduced primate-derived 
cells the best in both studies, demonstrating that Ad5 may be well adapted to this species. 
Determination of the viral particle number by real-time PCR in transduced myoblasts of 
different species revealed two putative barriers. A post-internalization block may occur in pig 
and ape myoblasts, where high numbers of intracellular particles accumulated without 
expressing EGFP. In primary mouse and rat L6 myoblasts however, an early block may be 
present at the level of vector attachment and internalization, where low amounts of 
intracellular Ad5 and Ad19a particles were detected. 
The poor transducibility of non-human myoblasts by Ad19a may be explained by subtle 
changes in the glycosylation pattern of membrane proteins. In mammals, sialic acid (N-
acetylneuramic acid (Neu5Ac) terminates glycoconjugated sugars. Sialic acid is either linked 
α2-3 or α2-6 to β-D-galactopyranosyl (Gal), β-D-N-acetyl-galactosaminyl (GalNAc) or β-D-
N-acetylglucosaminyl (GlcNAc) residues. Sialic acids are further attached α2-8 to sialyl-α2-3 
residues, and form polysialic α2-8 homopolymers occurring on glycoproteins (e.g., on 
NCAM)309. Except for humans, all mammals share an enzyme that oxidizes N-
acetylneuraminic acid to N-glycolylneuraminic acid (Neu5Gc)310. Indeed, N-
glycolylneuraminic acid can act as host-range determination factor for neuraminidase-
sensitive pathogens like influenza A virus and rotavirus311,312,313. Viral mutants of influenza A 
virus with HA genes recognizing Neu5Gcα2-3Gal and Neu5Acα2-3Gal replicate in horses, 
where the content of glycolylated sialic acid in erythrocytes and trachea exceeds 90%, 
whereas a virus strain that recognized preferentially Neu5Acα2-6Gal was unable to 
replicate311. Whether similar effects determine the host range of adenovirus type 19a remains 
to be investigated. Interestingly, small amounts of Neu5Gc have been detected in fetal tissue 
and tumors, though humans are unable to synthesize Neu5Gc due to a deletion in the 
corresponding CMP-Neu5Ac-specific hydroxylase gene310. It was further shown that Neu5Gc 
was incorporated into human glycoproteins through a Neu5Gc-rich diet314.  
The obtained results warrant additional investigations into gene transfer efficiency and the 
elucidation of host-range determination factors for Ad5 and Ad19a. In order to translate the 
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results obtained from Ad5-mediated gene-transfer efficiency from the animal model to a 
human model, a similar evaluation of gene delivery efficiency by real time PCR to muscle 
tissue and other organs from different species may be useful. Results from Ad19a transduction 
experiments with non-human skeletal muscle cells, which were only poorly transduced, may 
suggest the development of a human explant model to study Ad19a-mediated gene transfer in 
vivo. 
 
4.3 Outlook - Finding new molecular targets to treat muscular dystrophy 
The current model of the molecular pathology of dystrophy deficiency includes several 
mechanisms in addition to mechanical membrane destabilization78. Deregulation of ion-
channel activity leading to abnormal Ca2+ homeostasis and protease activation, as well as 
absence of nNOS signaling to reverse muscle-contraction-induced vasoconstriction, may 
contribute to muscle pathology. In support of this theory, studies with C. elegans double 
mutant dys-1:hlh-1 dys-1 (dystrophin ortholog and hlh-1 MyoD homolog) identified dyc-1 as 
the suppressor of the locomotion impaired phenotype315. Dyc-1 encodes the C. elegans 
homolog of CAPON, a protein that regulates interaction of PSD-95 and nNOS in neurons. 
Though C. elegans lacks an obvious nNOS homolog, the ancestral role of the dyc-1 gene 
could be the regulation of PDZ domain-mediated complex formation. Reestablishment of a 
functional DGC-like signaling complex through upregulation of compensatory molecules or 
ectopic expression of synaptic scaffolding molecules (e.g., utrophin, alpha7 integrin) may 
partially compensate for dystrophin-deficiency. The interesting finding, that mitigation of the 
dystrophic phenotype in mdx mice overexpressing CT-GalNAc transferase was related to 
ectoptic expression of CT-modified α-DG and extrasynaptic utrophin localization, 
underscores the importance of glycosylation for regulation of protein localization and 
function84. In a subset of LGMD-2I patients, an exceptionally mild phenotype was 
observed64,316. It has been suggested that a reduced but still-functional α-DG glycosylation in 
satellite cells may allow for correct α-DG-laminin association in regenerating, but not in 
mature fibers where hypoglycosylation of α-DG and loss of α-DG-laminin connection 
occurs63.  
The temporary clinical benefit for some patients of corticosteroids, which increases the 
muscle strength, is well accepted. Inflammatory cytokines may be linked to NF-κB-regulated 
muscle wasting through nuclear translocation of NF-κB and subsequent loss of MyoD 
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mRNA317.  Proinflammatory cytokines are released upon muscle fiber injury from mast cells 
in dystrophic muscles and may provide the cytokine source that initiates inflammation318. In 
addition, microarray analysis of mdx muscle revealed enhanced activity of inflammation-
related molecules including cytokines and cytokine receptors (e.g., TNFα receptor, IL1, and 
IL4) upregulation of the endothelial leukocyte adhesion molecule Vcam1, upregulation of 
complement system genes (C1q, C3) and chemokine receptors318. Chronic inflammation in 
dystrophic muscle may thus induce downregulation of MyoD and contractile dysfunction, 
which may be implicated in non-functional muscle regeneration through NF-κB-mediated 
inhibition of cell-cycle exit. Targeting the regulatory pathway that involves cytokine-
dependent nuclear translocation of NF-κB may therefore release myoblast differentiation 
block and complement corticosteroid treatment. Whether the regenerative capacity of 
myoblast precursor cells (satellite cells) becomes exhausted during disease progression of 
muscular dystrophy or whether it can be restored is a matter of debate. In a recent study by 
Conboy et al., loss of regenerative potential in aged skeletal muscle was shown to be due to 
inadequate activation of Notch-1 by its ligand Delta319. Impaired regeneration in aged muscle 
may therefore be linked to insufficient activation and differentiation of satellite cells, rather 
than to their depletion. The underlying molecular mechanisms for impaired regenerative 
capacity of satellite cells in dystrophic muscles may be similar to those in aged muscle, and 
therefore Notch-1-defective activation of regeneration would also need to be addressed. 
Targeting positive and negative regulators of muscle growth has already proved useful in 
animal models of muscle dystrophy. Increasing the muscle mass in mdx mice by inhibiting 
myostatin, a negative regulator of muscle growth and satellite cell proliferation, led to 
functional improvement of dystrophic muscles320. Similarly, muscle-specific expression of 
insulin-like growth factor-1 (IGF-1) activated myogenesis and prevented muscle-fiber loss in 
mdx mice321,322. IGF-1 acts through activation of Ca2+-calmodulin dependent kinase (CaMK), 
leading to nuclear translocation of transcription factor NFAT and histone deactelyase-5 
(HDAC5) phosphorylation323,324. The recent advances in the field of vector development and 
the further elucidation of the molecular pathology underlying DMD are stimulating clinical 
and pharmaceutical research. A safe vector for therapeutic gene delivery should be non-
immunogenic, non-toxic and able to deliver the transgene exclusively to the tissue of interest. 
With this work adenovirus-mediated gene transfer was rendered muscle-specific. Though this 
may only be a small contribution towards the development of safe vectors for gene therapy, 
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all the efforts combined may ultimately bring vectors for gene therapy into the clinic and 
relief patients with hereditary diseases from their suffering. 
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